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The number of problem heroin users in Northern Ireland has grown over recent years, and 
with this growth the subject of substitute therapy as an option for those presenting for 
treatment has become a significant issue.  Decisions about arrangements for Northern 
Ireland must be evidence-based, and the Department commissioned Dr Karen McElrath of 
Queen’s University, Belfast, to carry out the present review.   
The Department has considered the review carefully and agrees with the central thrust of 
Dr McElrath’s recommendations. Given the potential risks attached to substitute 
prescribing discussed in the review – for example the consequences of diversion and 
subsequent unauthorised or accidental use – the Department has qualified its response in a 
number of areas. The views of the Department are set out in the Appendix to the review.   
 
The Department will shortly establish an Implementation Group to oversee the 
development of structures to support those practitioners dealing with clients for whom 
substitute therapy is appropriate.  These structures will support practitioners to deliver 
services based on relevant clinical guidelines.  The Implementation Group will also 
consider how services should be configured to take account of logistical and resource 
issues.   
 
Substitute therapy as a treatment for heroin dependence has not been hitherto used on any 
significant scale in Northern Ireland.  The Department is committed to a thorough process 
of monitoring and evaluation to ensure that services are delivered appropriately; to 
maintain public confidence; and to update guidelines and advice to professionals in an 
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The second draft of this review of research was received by the 
Department in October 2002.  Although discussions between the author and 
the Department on the review continued after that date, the review does 





This report draws from extensive literature on subscribing prescribing for 
opiate dependence, and focuses largely on heroin use.  The report includes an 
international review of both clinical and observational studies.  Most 
research has focused on methadone, largely because of its longer history for 
treating heroin dependence.  The review includes findings from studies that 
have compared methadone, buprenorphine (Subutex), and to a lesser extent, 
Levo-Alpha-Acetyl Methadol and heroin maintenance.  The effects of these 
drugs on persons dependent on heroin and other opiates are examined in 
relation to outcomes, e.g., treatment retention and subsequent opiate use. 
 
The review identified dozens of controlled and observational studies from 
various countries that have reported favourable outcomes with respect to 
the effects of methadone treatment for heroin dependence.  This literature 
strongly suggested that methadone maintenance be implemented as a 
treatment option for persons dependent on heroin in N. Ireland.  Several 
factors (e.g., maintenance rather than reduction or abstinence programmes, 
dosage levels and flexible dosing policies, treatment in conjunction with 
counselling), however, were shown to increase or decrease the degree of 
successful treatment outcomes and programmes should be organised 
accordingly.  Additionally, it was recommended that reduction programmes 
be an option for heroin users as well, however, this decision should be an 
informed one, following balanced advice from drug treatment specialists or 
physicians.      
 
Diverted methadone that results in improper use of the drug is a primary 
concern, however, the review found that programme regulations such as 
supervised consumption of methadone appears to reduce methadone-related 
deaths.  This literature led to the recommendation that methadone clients 
undergo supervised consumption of methadone for the first six months of 
treatment and that drug treatment specialists and physicians consider the 
possibility of take-home doses after that time.  Alternatively, the research 
suggested that supervised consumption of methadone might reduce the 
number of clients who otherwise might be interested in methadone 
treatment, and might also affect treatment retention.  The research also 
identified limitations associated with programmatic urinalysis during 
treatment and called into question its effectiveness.         
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The review found that in some instances (e.g., proper dosage), buprenorphine 
was found to be as effective as methadone.  However, little is known about 
the long-terms of buprenorphine.  Additionally, Levo-Alpha-Acetyl Methadol 
is no longer available in several European countries because of serious 
adverse effects. The review also noted that although heroin maintenance 
appears to have some effect on drug-related criminal activity, the effects 
on other outcomes (e.g., relapse) are considerably less clear.  Based on this 
information, it was recommended that the DHSSPS implement 
buprenorphine treatment for maintenance purposes, when research has 
documented favourable results with respect to long-term effects of the 
drug.  However, three of five of Consultant Psychiatrists who would likely be 
involved if substitute prescribing were introduced in N. Ireland favour 
buprenorphine over methadone, citing the safety record of buprenorphine.   
 
This report described models for implementing methadone maintenance and 
the shared care model of treatment delivery appears to offer promising 
results.  It is necessary, however, to provide detailed and regular training of 
general practitioners (GPs), pharmacists, and drug treatment specialists and 
the report describes ways to involve GPs and pharmacists.  It was noted also 
that the DHSSPS should provide alternatives to treatment access. 
 
The literature review identified research conducted elsewhere that 
suggested that problems with childcare may represent a significant barrier 
to treatment entry, among women in particular.  Although three of the 
Consultant Psychiatrists had not observed this problem among patients to 
date, they also noted that most patients have been male.  It was suggested 
that obtaining this information about persons already in treatment, may 
represent a biased sample.  It was therefore recommended that childcare 
be provided by treatment specialist agencies in N. Ireland.       
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1   Introduction 
 
The medical implications of heroin use are noteworthy (O’Connor and Fiellin, 
2000).  Heroin injection can result in skin abscesses, considerable vein 
damage, and contribute to various bacterial infections resulting from 
injection practices (Centers for Disease Control, 2001).  The risk of 
acquiring blood-borne infections also is associated with injection behaviours.  
Heroin injectors are at risk for HIV, Hepatitis B and C viruses (Crofts, 
Aitken, and Kaldor, 1999; Hope et al., 2001; Long et al., 2001).  Inhaling the 
vapours from heated heroin (i.e., “chasing”) has been linked with 
leucoencephalopathy (Wolters et al., 1982), a rare disease but one 
associated with high mortality (Hill, Cooper, and Perry, 2000).  Mortality 
rates among heroin users are high.  In a 33-year follow-up study of 581 male 
heroin “addicts” who were required to undergo drug treatment between 1962 
and 1964 in California, the mortality rate among male heroin addicts was 
estimated to be 50 to 100 times the rate of the general male population of 
the same age group (Hser et al., 2001).   
 
Recent estimates, generated through capture-recapture methodology, 
suggested that there were between 695 and 1,018 problem heroin users in 
Northern Ireland during the 12-month time period, 1 November 2000 and 31 
October 2001 (McElrath, 2002).  During the same 12-month period, 361 
individuals who were using heroin sought treatment or attended a drug 
service for at least one day.  These figures suggest that between 36% and 
52% of problem heroin users sought treatment for heroin use during the 12-
month period.  Treatment outcomes (e.g., retention, reduction in or 
abstinence from heroin use) are not known for these individuals, however, an 
earlier qualitative study that focused largely on Belfast heroin injectors 
suggested that most of the 43 respondents either had never sought 
treatment or had failed to complete treatment for heroin dependence.  
Among those persons who had entered drug treatment for heroin 
dependence, lengths of stay in treatment were very brief and more 
accurately measured in terms of days rather than weeks or months 
(McElrath, 2001).       
 
Drawing in part from the definition proposed by Matheson, Bond and Hickey 
(1999), substitute prescribing for heroin dependence can be described as 
“the deliberate prescribing of drugs in a controlled manner” in order to 
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“reduce the use of illicit drugs” or to reduce the harm associated with illicit 
drug use.  This definition suggests that substitute prescribing can occur in 
maintenance or reduction programmes.  Marsden et al. (1998: 244) 
distinguished between these two types of programmes.  They noted that 
treatment retention is the critical component of maintenance programmes 
whereby “the substitute [drug] is administered at a stable level for a period 
of several months and sometimes years.” Maintenance treatment through 
substitute prescribing allows heroin users “to get on with their lives” 
although complete abstinence might never be achieved (Drucker, 2000: 33).  
In reduction programmes, patients are prescribed a substitute drug for 
heroin dependence and subsequently stabilized.  A gradual reduction of 
methadone dosage levels occurs thereafter.  The entire process is often 
short-term but can last for several months (Marsden et al., 1998).     
 
This report addresses the potential treatment use of substitute prescribing 
for heroin dependence in Northern Ireland.  In the United Kingdom, 
methadone and buprenorphine are licensed drugs that are available for the 
treatment of opiate dependence.  Diamorphine is also permitted under 
special license from the Home Office.  Other drugs, e.g., lofexidine, are 
available in the United Kingdom for detoxification or “drug reduction” only 
(Department of Health, 1999), however, the effectiveness of substitute 
drugs used for detoxification is a topic that is not addressed in this report.1    
 
Internationally, there exist a number of drugs that are utilised for the 
treatment of heroin dependence and this report begins with a description of 
the more common substances that are used for this purpose.  Within this 
section and where possible, the descriptions of each substance include 
research findings that pertain to the effectiveness of the substitute as a 
treatment for heroin dependence.  However, the vast majority of this 
research, including clinical trials and observational studies, has focused on 
the effectiveness of methadone treatment as opposed to other drug 
substitute interventions.  This report describes research findings that 
identify aspects of programmes, joint interventions, characteristics of 
individuals, and other factors that have been found to contribute to 
                                                 
1 Detoxification is generally not considered to be drug treatment.  Rather, detoxification is 
viewed as one of the initial stages in which opiate dependent persons must engage in order 
to subsequently reduce their intake of opiates.  Gabbay, Jeffrey, and Carnwath (2000) 
noted the confusion in the literature regarding the terms “reduction” and “detoxification.” 
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treatment outcomes, e.g., treatment retention, subsequent use of opiates or 
other drugs, and other lifestyle changes.  More recent studies have 
compared treatment outcomes for two or more substitute drugs and these 
studies are highlighted herein.  The report identifies a number of 
methodological problems that have been associated with studies that 
examine the effectiveness of substitute prescribing.               
 
This report includes a discussion of various programmes that offer 
substitute prescribing.  Most of this information is drawn from programmes 
located in Dublin, Glasgow, and Edinburgh.  In particular, the role of general 
practitioners and pharmacists are described in the context of a “shared 
care” delivery of drug treatment.  The review of various literature has 
identified several problems and issues that must be addressed before 
substitute prescribing is implemented and these factors are described.  The 
final sections of this report include a summary of major findings and a list of 




2  Substitute drugs used in the treatment of opiate dependence 
 
2.1  Methadone   
 
Methadone is a synthetic opiate that was developed in Germany in 1941.  In 
the 1960s, the drug was identified as a possible treatment for opiate 
dependence.2 Initial clinical trials conducted by Dole and Nyswander (1965) 
showed positive results and those scientists received the Lasker prize for 
their discovery (Drucker, 2000).   
 
Used orally, a single dose of methadone can last for 24-36 hours (Lindesmith 
Center-Drug Policy Foundation, 2000).  Initial doses (e.g., the first three 
days) must be within a “safe range” and increases in dosage levels can occur 
thereafter.  However, methadone clients must be monitored frequently, 
particularly when dosage levels are modified.  The correct dose diminishes 
withdrawal associated with heroin use as well as cravings for that drug.  
Withdrawal symptoms associated with heroin use can be minimised with low 
doses of methadone, however, high doses are required to block the effects 
of heroin (Lindesmith Center-Drug Policy Foundation, 2000).  The effects of 
sedation and euphoria do not occur if the correct dose of methadone is used.  
The goal of methadone treatment is to “establish a stable blood level of 
methadone such that the patient is neither too high (intoxicated) nor too low 
(in withdrawal)” (Drucker, 2000: 37).   
 
2.1.1  Outcomes associated with methadone treatment  
 
Both methadone maintenance and methadone-treated opioid reduction 
programmes are available in the United Kingdom.  Most outcome-based 
research into the effectiveness of methadone has focused on methadone 
maintenance so that little is known about the effectiveness of methadone 
reduction programmes (Gabbay, Jeffrey, and Carnwath, 2000; Seivewright 
and Iqbal, 2002).  In one comparative study, however, Sees et al. (2000) 
found methadone maintenance to be significantly more effective than 
methadone reduction.  Those authors randomly assigned 179 adults to either 
1) methadone maintenance (MMT) combined with one hour of group therapy 
                                                 
2 Methadone is used primarily to treat heroin dependence but can be used to treat other 
forms of opiate addiction as well.  Most research into the effectiveness of methadone 
treatment has focused on samples of heroin users.   
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per week and one hour of individual therapy per month, or 2) a methadone 
reduction program coupled with enhanced psychosocial services and 
aftercare (M180).  The reduction program included methadone provision for 
180 days with continued involvement in other services for the remaining six 
months.  Methadone dosage levels in both groups were comparable.  The 
researchers found no significant differences in opiate-negative urines until 
the fifth month of the study after which the M180 group showed a 
significantly higher rate of opiate-positive urines.  That pattern continued 
until month 12.  These findings suggested that maintenance programmes are 
more effective than reduction programmes, even when the latter are 
combined with enhanced support services.       
 
Methadone maintenance interventions have been widely researched – much 
more so than other substitute prescribing methods for heroin addiction 
(Farrell et al., 1994).  Scholars have noted that the majority of studies into 
the effectiveness of methadone treatment have been conducted in the 
United States (Marsden et al., 1999) and the degree to which US research 
findings are generalisable to Northern Ireland is unknown.  Clearly there are 
differences in the way that methadone is administered in the United States 
compared to certain European countries, including England, Scotland, and the 
south of Ireland.  In the US, methadone treatment slots are quite limited, 
the drug is only available through specialised clinics, and recommended 
dosage levels are low in comparison.   
 
Substitute prescribing has been available in Scotland, England and Wales for 
several years, however, clinical studies from those regions are limited.  
Moran et al. (2001) observed that although a growing body of research has 
investigated injecting drug use in the Dublin area, very little is known about 
the impact of methadone prescribing in the region.    
 
Research has demonstrated that the risk of premature death through either 
overdose or natural causes is lowered among heroin users who have been 
maintained on methadone compared with heroin users who have left 
methadone programmes prematurely (Caplehorn et al. 1994; Fugelstad et al., 
1995; Langendam et al., 2001).   
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Marsch (1998) used meta-analysis3 to examine the effectiveness of 
methadone maintenance on various behavioural outcomes, i.e., risk behaviours 
for HIV, criminal activity, and illicit opiate use.  In comparison to other 
outcome measures, she found that methadone maintenance had its largest 
impact on reducing drug-related crime (but not criminal activity in general).  
Moderate effects were noted for the reduction of opiate use and small to 
moderate but significant effects were observed for decreased risk 
behaviours for HIV infection (see below).  The author acknowledged the 
limitation that her study included only those samples in which all individuals 
completed methadone treatment.        
 
A large body of research has suggested that methadone can reduce at least 
some risk behaviours associated with HIV infection (Hoffman et al., 1998, 
Peters et al., 1998, Sorensen and Copeland, 2000; Wells et al., 1996).4  
Although considerable literature suggests that methadone treatment 
reduces the use of opiates (Ball and Ross, 1991; Hubbard et al., 1997) and 
risky injection practices (Ward, Hall, and Mattick, 1999), the evidence 
appears to be inconclusive regarding the link between methadone treatment 
and sexual risk behaviours.  Some research has found that participation in 
methadone treatment is followed by a decrease in the number of sexual 
partners and an increase in condom use.  For example, in a Miami, Florida 
study, Lollis et al. (2000) compared methadone clients with injecting drug 
users not-in-treatment (N=123).  Higher frequency of condom use, fewer 
sexual partners and fewer “high risk” sex partners were reported among 
methadone clients at six-month follow-up, compared to IDUs not in 
treatment.  Still though, other research has found that methadone 
treatment has had little impact on sexual risk behaviours (Magura et al., 
1998; Stark et al., 1996).  Research on injection drug users in general 
                                                 
3 Meta-analysis is a useful tool for examining a number of studies that focus on, for 
example, the effectiveness of drug treatment.  The strategy incorporates findings from 
various studies (with specified criteria for inclusion), and identifies those factors that are 
significantly related to outcomes, e.g., successful treatment completion.  The methodology 
has other benefits as well, including the potential for resolving discrepant findings from a 
number of studies (Farré et al., 2002).   
4 Sorensen and Copeland (2000) reviewed 33 studies that focused on drug treatment and 
HIV prevention. The studies were published between 1988 and 1998. The authors concluded 
that evidence was inconclusive with respect to the impact of drug treatment on selected 
HIV risk behaviours, namely, the loaning and borrowing of injection equipment as well as 
unsafe sex behaviours.   
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(without specific reference to methadone treatment) has documented that 
changes in injection and drug use risk behaviours have been more pronounced 
than changes in sexual risk behaviours.   
 
Zaric, Barnett, and Brandeau (2000) concluded that although some risk 
behaviours appear to be largely unaffected by methadone treatment, the 
risk reductions that are associated with such treatment are sufficiently 
large enough to have a significant effect on reducing HIV infection.  Those 
authors found that costs associated with HIV health care are increased with 
expansion of methadone maintenance in the United States.  However, these 
costs are offset by a reduction in expenditures associated with the 
prevention of new infections, decreases in injecting drug use, decreases in 
disease and ailments that are associated with injecting drug use, as well as 
lowered mortality.  Metzger et al. (1993) found that out-of-treatment IDUs 
had rates of HIV seroconversion that were six times as great as regular 
methadone clients.  The impact of methadone on the prevalence of Hepatitis 
C Virus has been considerably less.          
 
Many methadone clients return to heroin use after they have dropped out or 
completed treatment.  However, some studies that have focused on long-
term follow-up of methadone clients have shown promising results.  For 
example, Byrne (2000) followed 86 methadone clients who had participated 
in methadone treatment in Sydney between 1987 and 1988.  Follow-up data 
were collected in 1996, about nine years later.  The author noted that 41% 
of clients had remained in treatment during that time period.  By follow-up, 
eight persons had died and seven persons could not be located.  Examining 
data on subjects’ progress, the author estimated that between 56% 
(conservative estimate) and 81% (optimistic estimate) were doing well nine 
years later.  One limitation of this study was that there was no control 
group.  However, longer follow-up periods with good outcomes have reported 
elsewhere in Australia (Reinart, 2000).   
 
Schwartz et al. (1999) examined follow-up data for 21 methadone 
maintenance clients in Baltimore, Maryland (US).  Clients were monitored by 
a general practitioner and provided urine samples on a monthly basis.  Twelve 
years after enrolment, treatment retention was observed to be low (i.e., 
28.6%), however, self-reported quality of life was enhanced, and methadone-
related overdoses were non-existent even with monthly take-home doses.  
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Moreover, the authors found little evidence of diverted methadone being 
used for illicit purposes.            
 
Most studies of the effectiveness of methadone have focused on oral 
methadone.  Considerably less is known about injectable methadone, which 
has been available for prescription in the UK since 1968, although a 
randomised UK clinical trial of injectable versus oral methadone is in the 
pilot stages (Beaumont, 2001).   
 
Until early 2002, injectable methadone (unlike prescribed diamorphine) 
required no special licence in the United Kingdom.  However, new licensing 
arrangements were implemented in 2002 whereby physicians in the United 
Kingdom must now be licensed if they intend to prescribe injectable 
methadone.  This form of methadone has been used in some clinics and 
prescribed by some GPs when clients have responded poorly or have been 
resistant to oral methadone.  Some have claimed that injectable methadone 
also addresses the needle fixation that some clients exhibit.  Farrell et al. 
(1994) noted that clients who are offered injectable methadone might 
actually increase their frequency of injecting other drugs.  However, those 
authors noted the paucity of research comparing injectable and oral forms 
of methadone treatment and called for additional research into this issue.     
Ford and Ryrie (1999) found that GPs in England who have provided 
injectable methadone have based those decisions on various factors, e.g., 
previous poor outcomes with oral methadone, the length of injection history, 
extent of community support.  That study also focused on 34 patients who 
had been prescribed injectable methadone.  The authors observed that 
methadone dosage was reduced on 23 occasions over time and increased on 
two occasions only.  Beaumont (2001) surveyed GPs in England and Wales 
about injectable methadone prescribing.  Dose levels ranged from 20 to 300 
mg per day.  When given the choice between prescribed heroin and 
injectable methadone, some clients have chosen the latter (Metrebian et al., 
2001).   
 
2.1.2  Factors that contribute to methadone treatment outcomes 
 
Research has suggested that certain factors affect either continued opiate 
use during methadone treatment, relapse following treatment, or treatment 
retention.  In their extensive review of the literature, Farrell et al. (1994) 
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concluded that effective methadone treatment outcomes are associated 
with 1) good quality counselling, 2) good relationships between staff and 
patients, 3) effective management, 4) low staff turnover, 5) methadone 
doses in excess of 50 mg per day, 6) maintenance rather than abstinence as 
a treatment goal, and 7) no withdrawal of privileges.  Of importance to 
Northern Ireland treatment providers, higher rates of opiate use during 
methadone treatment have been linked with post-traumatic stress disorder 
(PTSD), notably exposure to violence during adulthood and physical and 
sexual abuse during childhood (Hien et al., 2000).  However, PTSD was not 
associated with treatment retention.      
 
Retention in methadone maintenance has been identified as a critical factor 
and length of stay in methadone treatment has been linked with reductions 
in illicit opiate use and criminal activity (National Evaluation Data Sources, 
2000).  Further, considerable evidence has suggested that methadone 
dosage is one of the most important factors for retaining clients in 
treatment.  Robles et al. (2001) suggested that methadone dosage levels 
appear to be both the most important and most researched factor relating 
to the effectiveness of methadone treatment.  Citing research, they noted 
that dosage levels are related to treatment retention and to diminished use 
of opiates among methadone clients.    
       
In maintenance programmes, methadone dosage levels are slowly increased 
to achieve stabilised levels and because individuals will respond differently 
to changes in dosage levels, dosages should be adjusted accordingly.  
Individual metabolism can affect ho w individuals respond to methadone 
dosage levels.  Tolerance to opiates as well as body weight have been 
identified as other factors that can affect an individual’s response to the 
drug (Lindesmith Center-Drug Policy Foundation, 2000).  A growing body of 
research has suggested that methadone doses might need to be increased in 
areas characterised by unusually high purity heroin (Bach and Lantos, 1999; 
Leavitt et al., 2000).     
 
Flexible methadone dosing policies is a critical factor that has been linked to 
treatment retention.  Earlier research found that approximately 50% of 
methadone clients in the US had been given doses at levels that were unable 
to prevent subsequent opiate use (D’Aunno and Vaughn, 1992).  Further, 
many programmes have maintained a fixed methadone dosing policy whereby 
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a 100 mg daily dose has been determined to represent the maximum 
allowable daily dose (Leavitt et al., 2000).  In reviewing the study by Ezard 
et al (1999), Ling, Huber, and Rawson (2001) noted that as many of 85% of 
patients in that study were “receiving inadequate doses” of methadone.  
Such policies fail to consider the individual needs of the patient.  The choice 
of the correct dosage level for a particular patient should be guided by 
information provided by the patient,5 the amount of time between 
methadone consumption and the patient’s symptoms, and consideration of 
changes in symptoms after dosage levels have been increased (Leavitt et al., 
2000).  Some methadone clients can be comfortable with 50 mg per day, 
whereas others will require more than 100 mg per day (Payte and Khuri, 
1993).  Dosage levels that fail to block the effects of opiates, fail to 
minimise withdrawal symptoms, and fail to reduce cravings offer little in the 
form of treatment to the patient and are not cost-effective.    
 
Some researchers have recommended that 60 mg of methadone per day is  
needed for stabilisation.  Such dosage would be required for high rates of 
treatment retention, to decrease the frequency of injecting drug use, and to 
prevent withdrawal symptoms (van Ameijden et al., 1995).  Some research 
has suggested that the provision of higher doses during detoxification 
reduces the likelihood of subsequent criminal activity.6  For instance, Bellin 
et al. (1999) examined reoffending (measured by the time period between 
release from jail and subsequent incarceration or end of study period) among 
prisoners in New York.  The authors compared inmates from four groups: 1) 
those who had received at least 60 mg of methadone while in jail, 2) those 
who had received 30 mg of methadone or less, 3) those who had been 
detoxed with methadone but who had not received methadone beyond the 
detoxification stage, and 4) those who had not received methadone at all.  
Recidivism was significantly lower in the high-dose group compared with the 
low-dose group; however, the difference was small between the two groups.  
The authors noted that their study relied on a fixed dose and that they 
were not permitted to examine the plasma levels of methadone.  They 
argued that the monitoring of plasma levels is important to determine 
whether the amount of methadone was able to achieve “adequate blocking 
                                                 
5 Leavitt et al. (2000: 410) reminded readers that Vincent Dole advised that clinicians 
should “listen to the patient” before deciding on dosage levels and adjustments.    
6 Or perhaps reduce the likelihood of being apprehended and convicted.   
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doses” for all clients.  They recommended that methadone plasma levels be 
examined routinely to determine “effective heroin blockade.”      
 
Weinrich and Stuart (2000) compared early studies from Glasgow and 
Edinburgh and observed that the average methadone dose prescribed in 
Edinburgh was 40 mg, a factor that may have been linked to the lower 
treatment retention rates (i.e., 39% at 12 months) in that city.  Average 
methadone doses in Glasgow were higher (i.e., 54 mg) as was the treatment 
retention rate in that city (i.e., 60%).  In an observational study, Caplehorn 
et al. (1993) estimated that a 1 mg daily increase in methadone resulted in a 
2% reduction in using heroin during methadone treatment.  Further, clinical 
trials have indicated that methadone doses of 80 to 100 mg per day are 
more effective than doses of 40 to 50 mg per day (Strain et al., 1999).  The 
higher doses contributed significantly to decreases in opiate use and 
increases in treatment retention.7  After 30 weeks of treatment, the 
percentage of opiate-positive urine samples was 53% for the high-dose 
group and 61.9% for the 40 to 50 mg group.  Reviewing the findings of the 
Strain et al. study, Leavitt et al. (2000: 408) suggested that despite the 
significant difference between the two groups, the substantive difference 
between 53% and 61.9% was “modest.”  Leavitt et al. (2000: 408) concluded 
that dosage levels in the Strain et al. study “were clearly subtherapeutic for 
many patients.”  In a review of various literature on methadone treatment, 
Barnett and Hui (2000) recommended that methadone is cost-effective if 
dosage levels are adjusted to meet individual needs (i.e., flexible dosing) and 
when high doses of methadone are permitted.  It is important to note, 
however, that methadone maintenance has shown to have little effect on the 
use of other illicit drugs (Gabbay, Jeffrey, and Carnwath, 2000).  Rather, 
methadone is intended to treat opiate dependence only.   
 
Clients who are made aware of the dosage level that they are consuming and 
clients who participate in decisions about dosage levels are more likely to 
refrain from using opiates (Havassy, Hargreaves, and De Barros, 1979; 
Robles et al., 2001) and to stay in treatment for longer periods (Caplehorn 
and Bell, 1991).  Condelli and Dunteman (1993) found that methadone clients 
who were informed of the dosage that they were consuming were 
approximately three times as likely to remain in treatment compared to 
                                                 
7 All methadone clients in that study received substance use counselling as part of 
treatment. 
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clients who were not told about their dosage levels.  Dosage also appears to 
“interact” with clinic attendance.  Rhoades et al. (1998) randomly assigned 
150 opiate users to one of four groups, modified by the daily dose of 
methadone (50 or 80 mg) and frequency of clinic attendance (two or five 
days per week).  Study retention was lower among clients who visited the 
clinic five days per week as opposed to two, thus treatment retention was 
higher among clients who received more take-home doses of methadone.   
Additionally, higher rates of opiate positive urines were reported for clients 
who had received low doses of methadone.   
 
Other factors that have contributed to successful treatment outcomes (e.g., 
retention, drug-free urine samples, injection drug use) among methadone 
clients have included gender, i.e., female (Gogineni, Stein, and Friedmann, 
2001; Staedt, 1996), not living with a substance-using partner (Gogineni, 
Stein, and Friedmann, 2001), and fewer social connections with drug using 
networks (Gogineni, Stein, and Friedmann, 2001).  A multivariate analysis 
conducted by Morral et al. (1999) showed that attendance at counselling 
sessions as well urinalysis results for opiates during the first two weeks of 
methadone treatment were factors that successfully predicted treatment 
outcomes at six- and nine-month follow-ups.      
 
2.2  Buprenorphine   
 
In 1978, buprenorphine (i.e., in this instance, Temgesic®) was introduced as 
a painkiller in the United Kingdom (Agar et al., 2001), however, Temgesic®, 
never proved to be an effective treatment for heroin dependence.  
Buprenorphine (in the form of Subutex®) is a partial opioid agonist that has 
been introduced as a treatment for opiate dependence in several European 
countries (namely France) as well as Australia.  Unlike methadone, 
buprenorphine is not orally active; rather, buprenorphine tablets are 
consumed sublingually, i.e., under or beneath the tongue.  Although 
buprenorphine is an opioid agonist, its antagonist properties mean that it 
“reacts against opiates and precipitates withdrawal” (Agar et al., 2001: 69).   
 
Advocates of the drug have argued that there are several benefits for using 
buprenorphine rather than methadone to treat heroin dependence.  First, 
buprenorphine is a partial opioid agonist so that with proper dosage, 
withdrawal from the drug is thought to be milder than withdrawal from 
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methadone or levo-alpha-acetyl methadol (Eissenberg et al., 1996; Lenné, 
Lintzeris, and Ritter, 1999; Schottenfeld et al., 2000).  Second, the effects 
of buprenorphine last longer than methadone so that dosing is less frequent 
than the daily dosing required with methadone.  Research has shown that 
buprenorphine, administered three times per week, is an effective dose for 
treating heroin dependence (Schottenfeld et al., 2000).  Third, the three-
day dosing schedule reduces the need for take-home doses, thus there is a 
reduced threat to the drug being sold or obtained through illicit purposes.  
Fourth, it has been suggested that buprenorphine is less likely than 
methadone to cause respiratory depression (Krook et al., 2002; Walsh et al., 
1994), a factor that could lower the rate of overdose.  However, Agar et al. 
(2001) have voiced concern about the effect of combining buprenorphine 
with “street” drugs.  Moreover, some authors have reported that high doses 
of buprenorphine can actually enhance the effects of certain drugs, i.e., 
cocaine (Rosen et al., 1993).      
     
Some researchers have found that high doses of buprenorphine (e.g., 12 mg) 
are more effective than low doses (Pani et al., 2000) whereas others have 
reported that buprenorphine doses that exceed 12 mg per day might be 
required for some patients (Schottenfeld et al., 1997).  Still others have 
suggested that because buprenorphine is a partial agonist, the drug may be 
less effective at higher doses (Barnett, Rodgers, and Bloch, 2001).  
Chadderton (2000) reported that the opiate agonist effects of 
buprenorphine reach a ceiling effect estimated at 10 to 12 mg per day.       
 
As a method for treating heroin addiction, buprenorphine was approved in 
2000 in Australia, and the drug (i.e., Subutex®) has been available in that 
country since 2001.  Given its recent introduction in Australia, the literature 
describing the experience of buprenorphine there is quite scant.  
Considerably more research on buprenorphine as a treatment for opiate 
dependence has emerged from France where the drug (i.e., Subutex®) was 
approved as a treatment for heroin dependence in France in 1995 and has 
been available in pharmacies since 1996 (Reynaud-Maurupt et al., 2000).  In 
that country, the drug is available in .4, 2, and 8 mg tablets.  The 
recommended daily dose is between 8 and 10 mg.  For maintenance purposes, 
clients collect doses from pharmacies and take-home doses (28-day 
maximum) are permitted (Ling, Huber, and Rawson, 2001).   About 60,000 
patients were receiving buprenorphine in France in the late 1990s, 
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approximately seven times the number who were in receipt of methadone 
(Thirion et al., 2002).  Ling, Huber, and Rawson (2001: 82) reported that 
heroin-related overdose deaths decreased by about 50% since 
buprenorphine and methadone were made available in the country.  Those 
authors also noted that “general health status and quality of life” have 
improved among heroin users who have exposed to the intervention.       
 
In France, any physician can prescribe buprenorphine, however, methadone  
(made available during the same year as buprenorphine) must be prescribed 
initially through specialised care centres.  Following stabilisation, GPs can 
prescribe but will also “liaise” with the care centres.  There is very limited 
space for methadone treatment and this limitation, coupled with fewer 
prescribing restrictions for buprenorphine as opposed to methadone 
probably contributed to the huge disparity in the numbers of clients in 
receipt of buprenorphine and methadone in the country.  Although 
methadone and buprenorphine have both been available in France since 1996, 
physicians have been issued very few guidelines as to which drug should be 
prescribed for particular patients (Thirion et al., 2002).   
 
Illegal street sales of buprenorphine have been reported in a host of 
countries, including England, Scotland, Bangladesh, and Australia (Agar et al., 
2001).  Prescribed buprenorphine has been sold on the illicit market in 
France, where Kempfer (2000) noted the potential for extreme damage to 
veins and skin when sublingual preparations of the drug are injected.       
 
To prevent buprenorphine from being diverted (i.e., sold or obtained illegally) 
onto the illicit drug market, efforts have focused on the combined 
preparation of buprenorphine and naloxone.8  For instance, Rosenheck and 
Kosten (2001: 254) have argued: 
 
“While harmless, if taken sublingually as prescribed,  
when the combined buprenorphine/naloxone preparation  
is injected into as opiate dependent person, it precipitates 
immediate and painful withdrawal and thus is not likely to  
be diverted for abuse.”  
 
                                                 
8 The combined preparation is of particular interest in the United States.   
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Those authors argued that a primary benefit of buprenorphine/naloxone is in 
regards to it “acceptability to society” (Rosenheck and Kosten, 2001: 254).   
 
However, controversy over this combined drug preparation is mounting.  
Some opponents have argued, for example, that such a policy assumes that 
drug users are “dishonest” and might impinge upon staff-client relationships 
in treatment settings.  Moreover, Byrne (2001) observed: 
 
“There are no parallels in other therapeutics as far  
as I can see that one would add a second drug to make  
the original drug more palatable to the community or  
regulatory authorities, but of no added benefit to the  
patient.”  
 
Any maintenance drug can be diverted for illicit purposes.  If the 
buprenorphine/naloxone preparation is diverted and then injected, the 
naloxone is absorbed which would produce withdrawal in opiate-dependent 
individuals.  The preparation is intended to be consumed sublingually, so that 
only the buprenorphine is absorbed (Barnett, Zaric, and Brandeau, 2001: 
1268).  Other authors have suggested that although buprenorphine/naloxone 
preparations might lower the likelihood of diversion, clients might also 
exhibit little interest in the combination drug within treatment settings 
(Agar et al., 2001).   
 
To date, studies of buprenorphine have focused on the short-term effects 
of the drug such that the effectiveness of the treatment in the long-term is 
unknown (Barnett, Zaric, and Brandeau, 2001).  Moreover, in reviewing the 
literature on buprenorphine, Gabbay, Jeffrey, and Carnwath (2000) failed to 
find any study that had examined the effect of buprenorphine treatment on 
employment and criminal behaviour among clients.      
 
2.3  Levo-Alpha-Acetyl Methadol     
 
Similar to buprenorphine, Levo-Alpha-Acetyl Methadol (LAAM) is a long-
acting opiate agonist that can be administered three times per week, in 
comparison to the daily dosing required with methadone.  The drug 
diminishes cravings for opiates and is said to block withdrawal symptoms 
associated with opiates (Lindesmith Center-Drug Policy Foundation, 2000).  
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LAAM is more expensive than methadone but since it can be dispensed every 
72 hours rather than daily, treatment costs are said to be lower for LAAM 
than for methadone (National Evaluation Data Services, 2000). 
 
Levo-alpha-acetyl methadol is currently available in clinic settings in the 
United States, but since April 2001 the use of LAAM in the European Union 
has been abolished, following the recommendation by the European Medicinal 
Evaluation Agency (European Centre for Drugs and Drug Addiction, 2002).  
Concerns over LAAM focused on its link with “unpredictable cardiotoxicity” 
(European Agency for the Evaluation of Medicinal Products, 2001: 1).  
Although the drug is not currently licensed as a treatment for opiate 
dependence in the United Kingdom, it is described herein because recent 
studies have compared its effectiveness to both methadone and 
buprenorphine.      
 
Risk of overdose from take-home doses of LAAM is a concern.  Effects of 
the drug are exhibited more quickly with injection rather than from other 
routes, yet even when the drug is injected, the effects do not appear until 
three to six hours after administration (Marsden et al., 1999).  Because the 
effects of LAAM take longer than methadone, some clients in the United 
States are prescribed both LAAM and methadone during the initial stages 
of treatment, after which the methadone is eliminated (Lindesmith Center-
Drug Policy Foundation, 2000). 
 
Valdivia and Khattak (2000: 401-402) suggested that LAAM should be 
utilised rather than methadone 1) when patients have difficulty collecting 
daily prescriptions, 2) for patients who have a history of poor treatment 
outcomes with somewhat high doses of methadone, e.g., more than 60 mg per 
day, 3) for clients who are suspected of diverting methadone onto the illegal 
drug market, 4) for patients who are concerned about drug testing in the 
workplace (the authors noted that urinalysis does not often screen for 
LAAM), 5) for patients who report extreme sedation while taking 
methadone, 6) for patients who are “rapid metabolizers.”  However, as 
mentioned previously, the negative effects of the drug have created 





2.4  Heroin maintenance 
 
Prescriptions for diamorphine in the UK can only be written by a medical 
practitioner who has been granted a special license by the Home Office.  In 
England and Wales, Sell, Farrell, and Robson (1997) estimated that there 
were approximately 42 physicians who maintained special licenses to 
prescribe diamorphine in the mid-1990s.  Heroin prescriptions, however, 
represent only a very small minority of prescribed opiates in England and 
Wales.  With its thrice daily dosage, the treatment is considered to be 
expensive in comparison to methadone (Gabbay, Jeffrey, and Carnwath, 
2000).  Elsewhere, a randomised clinical trial showed that prescribed 
injectable diamorphine produced similar outcomes to injectable methadone 
(Strang et al., 2000).  A non-randomised study by Metrebian et al. (1998) 
confirmed these findings.  McCusker and Davies (1996) found that persons 
who were prescribed diamorphine had higher rates of treatment retention, 
and lower rates of psychopathology and hopelessness compared to persons 
who had been prescribed methadone.  However, cocaine use was significantly 
higher among persons who had been prescribed heroin.         
 
Heroin maintenance programmes were implemented in Switzerland in 1992 
and randomised trials have been conducted in Geneva (Perneger et al., 
1998).9  In the latter study, subjects were randomly assigned to either 
heroin maintenance or an alternative treatment programme of their choice 
(most often, methadone) and re-assessed six months after baseline.  
Treatment retention in the control group was not examined and all outcome 
data were measured through self-reports.  At six-month follow-up, the 
experimental group had reduced levels of risky injection practices, lower 
rates of anxiety, reduced number of suicide attempts, reduced aggression, 
and better control over aggression violent behaviours.  No significant 
differences were found in self-reported depression, social functioning, 
income levels, or condom use.   
 
In their review of the literature, Gabbay, Jeffrey, and Carnwath (2000) 
concluded that heroin (diamorphine) maintenance has shown to reduce 
criminal activity but with little effect on subsequent use of illegal 
substances or social functioning.  In commenting on the findings from the 
                                                 
9 Trials are planned in Germany beginning in 2002. 
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Swiss trials, Farrell and Hall (1998) noted that heroin maintenance may 
represent a treatment option for persons who respond poorly to methadone.   
Randomised trials of heroin maintenance commenced in the Netherlands in 
1997.  The effectiveness of the intervention within that country might 
provide evidence of the benefits of such treatment.  However, Hartnoll 
(1999) argued that large numbers of out-of-treatment heroin users within a 
given region would need to participate in heroin maintenance treatment for 
the intervention to impact substantially on the prevalence of problem heroin 
use.   
 
2.5  Substitute treatment in the European Union and Norway 
 
Table 1 provides a summary of the type of substitute treatment that is 
available for opiate users in the European Union and Norway.  The data were 
drawn from a report issued by the European Monitoring Centre for Drugs 
and Drug Addiction (2002).  There are a number of limitations to this 
information.  First, in some instances the tabular data from the original 
report differed from the text.  Second, some countries reported an annual 
count by calendar year whereas other countries reported data for an 
alternative 12-month period.  Still others reported information from a one-
day census of persons in receipt of substitute treatment.  Third, it would 
have been helpful to know the percentage of opiate users who were in 
receipt of substitute treatment.  The authors of the original report 
attempted to do so, but information on the number of problem opiate users 
from various countries was limited.  However, Hartnoll (1999) estimated that 
substitute prescribing rarely is able to reach more than 50% of problem 
opiate users, even when a range of these interventions are available.  Fourth, 
in some instances it was unclear whether the substitute drug was used for 
detoxification only or for short- or long-term maintenance.   Despite these 
limitations, Table 1 shows that at least some regions within all countries of 
the European Union (and Norway) offered some type of substitute 
prescribing for problem opiate users, and methadone was available in all 
countries.   
 
The report by the European Monitoring Centre for Drugs and Drug Addiction 
(2002) indicated that some countries (e.g., Denmark) implemented 
methadone treatment over 30 years ago, whereas others (e.g., Greece) did 
not offer methadone maintenance until the early 1990s.  Additionally, some 
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countries offered substitute treatment as a last resort.  In Greece, for 
instance, there were more than 4,000 persons on the waiting list for 
substitute treatment in 1999.  Waiting lists tended to be higher in those 
countries that used very strict criteria for admission (European Monitoring 
Centre for Drugs and Drug Addiction, 2002) and the admission criteria for 
substitute programmes differed greatly.  For instance, in Greece, criteria 
included injecting drug use, a minimum age of 22, a minimum of two years 
“drug addiction” and a history of one or more failed treatment attempts.  In  
contrast, Sweden required substitute treatment clients to be “have at least 
four years of documented intravenous opiate addiction,” to have at least 
made one attempt to engage in drug-free interventions, to be a minimum of 
20 years of age, and “to have medical records showing that there is no 
advanced multiple substance addiction involved” (European Monitoring Centre 




Table 1.  Substitute Treatment in the European Union and Norway 
 
Country  Drug Utilised (Number in Treatment)  Yeara 
   
Austria  Methadone (3,229)    2001 
   Buprenorphine and Morphine (1,664) 
 
Belgium  Methadone (7,000)    1996 
 
Denmark  Methadone (4,298)    1999 
   Buprenorphine (100) 
   LAAM (200) 
 
Germany  Methadone (32,100)    2000 
   Levomethadone (10,000)b 
   Buprenorphine (500) 
   Dihydrocodeine (3,700) 
 
Greece  Methadone (966)     2000 
 
Finland  Methadone (70)       --c 
   Buprenorphine (170) 
 
France  Methadone (10,000)    2001 
   Buprenorphine (74,000) 
 
Ireland  Methadone (5,032)    2000 
 
Italy   Methadone (66,550)    1999 
    
Luxembourg  Methadone (170)     2001 
   Mephenon (70) 
 
Netherlands   (11,676)d          1997 
 




Table 1, continued 
 
Country  Drug Utilised (Number in Treatment)  Yeara 
 
Norway  Methadone (1,100)     2001 
 
Portugal  Methadone (5,400)    2001 
   LAAM (600) 
 
Spain   Methadone (72,236)    1999 
   LAAM (206)  
 
Sweden   (621)d       2000 
 




a From the text and tabular data in the original report, it is unclear as to 
whether the time period represents a calendar year, another 12-month 
period, or a one-day census.   
 
b Verthein, Kalke, and Raschke (1998: 75) reported that “Levomethadone is 
about twice as efficient as methadone.”   
 
c Year was not reported. 
 
d Numbers are not categorised separately for drug type. 
 
Source:  Classifications of Drug Treatment and Social Integration and their 
Availability in EU Member States plus Norway (European Monitoring Centre 








2.6  Comparisons between two or more substitute drugs for the treatment  
of opiate dependence: Treatment outcomes 
 
2.6.1  Methadone and buprenorphine 
 
Studies that have compared buprenorphine with methadone generally have 
found higher rates of treatment retention among persons who have been 
administered methadone (e.g., Barnett, Rodgers, and Bloch, 2001; Eder et al., 
1998; Fischer et al., 1999; Petitjean et al., 2001).  However, methadone dose 
levels in these studies most often exceeded 50 mg per day.  In several 
studies, a low dosage level of either methadone or buprenorphine has been 
linked with lower study retention rates (Maddux, Prihoda, and Vogtsberger, 
1997),10 and low doses of methadone (e.g., 20 mg per day or less) in 
particular are said to be roughly equivalent to placebo-like conditions 
(Leavitt, 2002).  For example (Johnson, Jaffe, and Fudala, 1992) assigned 
subjects to either 8 mg per day of buprenorphine or 20 mg per day of 
methadone.  Retention was higher and opiate-positive urines were lower 
among subjects who were administered buprenorphine in comparison to 
methadone.  In their review of several studies that compared buprenorphine 
and methadone, Ling, Huber, and Rawson (2001: 81) concluded that subjects 
from both groups “perform comparably once a maintenance dose is reached, 
although it appears somewhat more difficult to begin treatment with 
buprenorphine than with methadone in highly opiate dependent patients.” In 
general, buprenorphine dosage levels between 8 and 16 mg are needed to 
produce similar treatment outcomes as achieved by high-dose methadone 
(Gabbay, Jeffrey, and Carnwath, 2000).    
 
A few studies have shown no significant differences in treatment outcomes 
when comparing the two drugs.  For instance, Pani et al. (2000) randomly 
assigned 72 opioid dependent subjects to one of two groups: 1) 8 mg of 
buprenorphine per day or 2) 60 mg of methadone per day.  The rate of drug 
positive urine samples and study retention did not differ significantly 
between the two groups.  The authors noted that their study was one of the 
first to use buprenorphine in tablet form, reflecting its availability in 
treatment settings.      
    
                                                 
10 Eight mg of buprenorphine is approximately equivalent to 30 mg of methadone.   
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Some fairly good recent reviews have used meta-analysis to compare the 
effectiveness of the two drugs, although authors have noted the difficulties 
in including studies that have relied on different methodological designs.    
Barnett, Rodgers, and Bloch (2001) conducted a meta-analysis of five clinical 
trials that used random assignment to examine the effects of methadone 
(50 to 80 mg per day) in comparison with buprenorphine (6 to 12 mg per day) 
among clients treated in methadone clinics.  Those authors observed that 
the extent of drug positive urine samples was significantly higher among 
clients in receipt of buprenorphine compared with methadone.  Moreover, 
retention rates in treatment were significantly lower among buprenorphine 
clients compared with methadone clients.  The authors concluded that 
although statistically significant differences between the two groups were 
observed, the magnitude of the differences was relatively small.     
 
A second meta-analysis that compared the effectiveness of methadone and 
buprenorphine was conducted by West, O’Neal and Graham (2000).  The 
authors identified nine studies that compared these two substitute drugs.  
The authors observed the difficulties in comparing across studies because 
of the different dosage levels that were utilised in the studies.  Equally 
important, the authors were limited to one outcome measure only, i.e., 
urinalysis results.  Based on this outcome, the authors concluded that the 
two drugs produced approximately equal rates of drug positive urines.  Also 
important, the researchers found that persons who had a prior history with 
methadone tended to do better with buprenorphine than persons who had no 
experience with methadone.  The authors noted, however, that more 
research is needed to investigate this issue.   
 
2.6.2.  Methadone and LAAM 
 
Glanz et al. (1997) used meta-analysis to compare the effectiveness of 
methadone and LAAM.  Those authors found that methadone produced 
higher retention rates than LAAM.  No significant difference was observed 
with respect to illicit drug use.   
 
2.6.3  Methadone, buprenorphine, and LAAM 
 
Farré et al. (2002) utilised meta-analysis to explore the effectiveness of 
low- and high-dose methadone, LAAM, and buprenorphine from 13 
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randomised, controlled studies.  High-dose methadone (i.e., 50 mg per day or 
more) was significantly more likely to result in decreases in illicit opiate use 
compared to low-dose methadone (less than 50 mg per day).  Retention rates 
did not differ significantly between the low- and high-dose groups.   
 
High-dose methadone was superior to low-dose buprenorphine (less than 7 
mg per day) but approximately equal to high-dose buprenorphine, in terms of 
reductions in opiate-positive urines.  Results for retention data showed 
similar results, that is, high-dose methadone was about equal to high-dose 
buprenorphine but produced significantly better results than low-dose 
buprenorphine.   
 
Comparisons between high-dose methadone and LAAM showed that the two 
interventions had approximately the same impact on reducing opiate-positive 
urines.  Retention, however, was higher for high-dose methadone.  Fewer 
opiate-positive urines were associated with low-dose methadone when 
compared with LAAM, but retention did not differ significantly between 
low-dose methadone and LAAM.           
 
Based on the results from their meta-analysis, Farré et al. (2002: 289) 
concluded that: 
 
“The new drugs, buprenorphine or LAAM, do not seem superior to 
methadone in terms of efficacy.  In our opinion, the most important 
advantage of LAAM and buprenorphine is the ‘3-days a week 
schedule…” 
 
The authors also noted that unlike methadone, studies that have examined 
buprenorphine or LAAM as they relate to criminal behaviour, HIV risk 
behaviours and other outcomes have yet to be examined.      
 
A 17-week study by Johnson et al. (2000) also compared methadone, 
buprenorphine, and LAAM.  A total of 220 heroin “addicts” were randomly 
assigned to one of four conditions: 1) thrice weekly buprenorphine dosing 
(16-32 mg per dose),11 2) thrice weekly LAAM dosing (75-115 mg per dose), 
3) daily methadone dosing (20 mg per dose), and 4) daily methadone dosing 
                                                 
11 Friday doses were higher for subjects in the LAAM and buprenorphine groups in order to 
allow for the additional days before the next dose was administered.    
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(60-100 mg per dose).  Doses were increased if attendance was satisfactory 
and subjects were not absent on a Friday.  Outcome measures included self-
reported heroin use, urinalysis results, and study retention.  Self-reported 
heroin use was approximately equal across groups.  The LAAM group had the 
highest percentage of 12 or more consecutive opiate-free urine samples 
(36%) and the high-dose methadone and the buprenorphine groups were 
approximately the same (28%, 26%, respectively).  Only 8% of the low dose 
methadone group had 12 or more consecutive “drug-free” urine samples.  
Moreover, persons in the low-dose methadone group had higher rates of 
cocaine use than subjects assigned to the other groups.  Subjects were 
asked to report the severity of problems associated with drug use.  
Subjects assigned to the buprenorphine group reported the lowest severity 
rating whereas persons in the low-dose methadone group reported the 
highest severity rating.  One problem with this 17-week study was the 
retention rate of 51%.  Moreover, retention varied across groups: High-dose 
methadone (73%), buprenorphine (58%), LAAM (53%) and low-dose 
methadone (20%).  It is not known whether subjects in this study were 
exposed to counseling or related interventions.      
 
Shortly after the Johnson et al. (2000) was published, the lead author was 
interviewed by the (US) National Institute on Drug Abuse.  Despite the 
comparison study that involved three substitute drugs and varying dosage 
levels, the lead author noted that information about the most effective 
match between patient and type of substitute drug still was lacking (National 
Institute on Drug Abuse, 2001).  In other words, research has yet to 
identify which patients will benefit most from a particular drug and which 
will benefit most from an alternative.  One report, however, indicated that 
buprenorphine might be more suitable than other drugs for people who 
exhibit high levels of psychosocial functioning (Resnick, Resnick, and 
Galanter, 1991).    
 
Leavitt (2002) examined reports of adverse effects associated with 
methadone, LAAM, and buprenorphine for a three-year period.12 The data 
were reported initially to the US Food and Drug Administration (FDA) and 
                                                 
12 Leavitt’s review appeared to be extremely thorough and he has published quite 
extensively on substitute prescribing.  However, a potential conflict of interest is worth 
mentioning here.  Leavitt is editor of the Addiction Treatment Forum On-line and that 
Forum is funded at least in part by a company that manufactures methadone and naltrexone.   
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re-analysed by the author.  A substantially higher number of adverse 
effects were associated with buprenorphine and LAAM, in comparison to 
methadone.  Moreover,  buprenorphine (57%) was more likely than 
methadone (26%) and LAAM (45%) to be listed as the “sole agent” that 
contributed to the adverse effects.   A similar conclusion was reached for 
morbidity and these prescribed drugs.  The author of the report 
acknowledged that the study was limited in that FDA data were not 
validated against external criteria.   
 
2.7  Substitute prescribing in conjunction with other interventions 
 
2.7.1  Treatment goals 
 
The programme philosophy often varies across substitute treatment 
programmes.  Some programmes are characterised by the treatment goal of 
abstinence whereby rules and regulations are designed to meet this 
objective.  Other programmes reflect a harm reduction philosophy, and 
recognise that some clients will need to be maintained on substitute drugs 
for years.  The goal of abstinence from all drugs may be inappropriate for 
several methadone clients.   Research has demonstrated that clients have 
tended to do better in methadone clinics that are characterised by 
treatment goals that incorporate continued maintenance rather than 
abstinence (Ball and Ross, 1991; Caplehorn, Lumley, and Irwig, 1998).  
Indeed, a study by Sees et al. (2000) suggested that programmes 
characterised by “abstinence only” ideologies - might negatively affect 
treatment outcomes.  Abstinence may be a goal suited for some clients but 
when this goal is not feasible, reducing harm to self and others should be 
the goal.  Treatment programmes that pose limits on the length of time in 
which a person can receive methadone generally have less successful 
treatment outcomes than programmes that pose no such restrictions 
(Caplehorn et al., 1993; McGlothlin and Anglin, 1981). 
 
 2.7.2  Counselling 
 
In their review of the literature, Gabbay, Jeffrey, and Carnwath (2000) 
concluded that methadone maintenance was more effective when used in 
conjunction with counselling, however, those authors suggested that 
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counselling for opiate-dependent persons in the absence of substitute 
prescribing had not been shown to be effective.  
 
In many regions, methadone clients generally are not required to undergo 
counseling.  For example, in the south of Ireland, counselling is available for 
clients in methadone maintenance, but is provided on a voluntary basis.  
Moran et al. (2001) reported that research has yet to be undertaken on the 
extent or impact of counseling on methadone clients in the south of Ireland.  
In Edinburgh, use of counselling services among methadone clients varied 
considerably in the early 1990s (Peters and Reid, 1994).  Similar claims have 
been reported in Glasgow (Gruer et al., 1997).  Mandatory counselling might 
lower treatment retention rates, and hence might prove to be counter-
productive.  Such a policy, for example, could undermine the goals of 
individual treatment plans.  Because of the possibility that some clients are 
not in need of regular counselling, requiring client participation in regular 
counselling might not be cost-effective.          
 
Although few studies have examined the joint effects of substitute 
prescribing and counselling, research that has been conducted shows 
promising results.  For example, McLellan et al. (1993), first stabilised 79 
males with 60-80 mg of methadone per day and then randomly assigned them 
to one of three groups:  1) minimum methadone maintenance, i.e., blocking 
doses of methadone coupled with emergency counselling and referral only, 2) 
standard methadone maintenance, i.e., blocking doses of methadone 
combined with regular counselling and contingency management involving 
take-home doses for attendance, employment, and negative urine samples, 
and 3) enhanced methadone maintenance, i.e., incorporating the factors from 
the other groups but including employment and family counselling, social work 
intervention, and medical and psychiatric care.  The authors found a 
significantly higher rate of drug positive urines were observed among clients 
assigned to the methadone only group.  By the end of the first three months 
of the study, 69% of the subjects in the methadone only group were either 
“protectively terminated” from the study or were transferred to the 
standard methadone group.  Similarly, within the first six months of the 
study, approximately 41% of the standard methadone group began to display 
the same behaviours (e.g., drug use) as many subjects in the methadone only 
group.  In contrast, only 19% of the enhanced methadone group fell within 
the protection termination category.   
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Weekly counselling held in conjunction with methadone prescribing has been 
shown to be more effective than methadone treatment without counselling 
(Ling, Huber, and Rawson, 2001, citing Rounsaville and Kosten, 2000).  
However, Ling, Huber, and Rawson (2001: 87) concluded that “extensive day 
program treatment within a methadone program has not produced better 
outcomes.” 
 
Barnett and Hui (2000) suggested that additional support services, e.g., 
counselling, may be of greater importance in the early stages of methadone 
treatment, however, the authors argued that more research is needed as to 
the cost-effectiveness of support services during the final stages of 
methadone treatment. 
 
2.7.3  Contingency management 
 
The philosophy of contingency management assumes that behaviours can   
change for the better when individuals are either provided with incentives 
or sanctioned with disincentives.  With respect to substitute prescribing, 
most research on contingency management has focused on short-term 
detoxification programmes.   Griffith et al. (2000) used meta-analysis to 
examine the effect of contingency management on illicit drug use (measured 
by urinalysis) during methadone treatment.  The authors found that 
incentives such as take-home doses and dosage increases and decentives 
such as thrice weekly urinalysis significantly contributed to reduced drug 
use during treatment.  Other researchers have focused on the role of 
contingency management as well as dosage on treatment outcome.  For 
example, Preston, Umbricht, and Epstein (2000) provided subjects with 50 
mg of methadone per day, and then randomly assigned them to one of four 
conditions 1) contingent vouchers for goods and services when urines were 
opiate-negative, 2) dosage increase to 70 mg per day, 3) contingent vouchers 
for negative urines coupled with dosage increase to 70 mg per day, and 4) 
maintain at 50 mg per day.  The authors found independent effects of 
methadone dosage and voucher rewards.  That is, both factors contributed 
independently to opiate-negative urine samples and lowered self-reported 
craving for heroin.   More research is needed with respect to the role of 
contingency management in conjunction with substitute prescribing in 
maintenance programmes.   
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2.7.4  Other programme aspects 
 
Many programmes exclude or terminate clients who fail to abide by 
programme rules and regulations.  More intensified care (in the form of 
behavioural reinforcement) in response to client instability in treatment 
shows promise (King et al., 2002), although more research is needed in the 
area of “stepped care” treatment.  Others have suggested that intensified 
care for clients who exhibit major adjustment problems takes into the 
consideration the concept of patient-treatment matching and is cost-
effective (Davison, 2000).    
 
2.8  Problems associated with studies that address the effectiveness of 
substitute drugs 
 
Studies, including clinical trials that have compared the effectiveness of one 
or more substitute drugs often are plagued by various methodological 
problems.  These problems are highlighted in the paragraphs that follow.   
 
2.8.1  Stringent study criteria, insufficient detail, and experimental  
conditions   
 
Study exclusion criteria often fail to reflect realistic profiles of heroin 
users, so that external validity is questionable.  For example, some studies 
exclude polydrug users whereas other research excludes drug users with 
psychiatric or mental health problems.  Research has suggested that in some 
regions - more than 60% of injecting drug users have contracted Hepatitis C 
Virus (Coppola et al., 1994), yet some studies exclude individuals who have 
been diagnosed with medical illnesses relating to the liver (e.g., Amass, 
Kamien, and Mikulich, 2001).  Such a criterion would thus exclude a 
disproportionate number of injectors and other drug users who have 
developed Hepatitis C Virus.  The effectiveness of substitute prescribing 
for persons who have been infected with Hepatitis C Virus requires further 
attention by researchers.  In a similar vein, other studies have included only 
those clients who were in full-time employment, excluding persons who were 
unemployed or who worked part-time (e.g., King et al., 2002).  Further, the 
vast majority of studies on treatment effectiveness exclude adolescents 
and very young adults, i.e., younger than 18 years, thus we know very little 
about the efficacy of methadone treatment among young heroin users.   
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Although some research includes joint interventions, e.g., methadone 
combined with counselling, too often these other interventions are not 
described with adequate detail.  The nature and quality of these other 
interventions, and how the quality might vary across clients often is not 
reported.  White, Alcorn, and Feinmann (2001) suggested that double-blind 
conditions as part of an experimental condition can be problematic because 
this condition generally prohibits flexible dosing of the substitute drug.  
Similar criticisms have been voiced about other studies (Leavitt, 2002).    
Prohibiting flexible dosing runs counter to good quality treatment.   
 
Finally, in several studies of the effectiveness of buprenorphine, 
researchers have utilised a liquid form of the drug, when in several 
countries, the drug is used in tablet form and administered sublingually.  
Nath et al. (1999) suggested that the bioavailability of buprenorphine from 
the tablets is considerably less than the bioavailability from the liquid form.   
Experimental conditions should reflect the form in which substitute drugs 
are available in treatment settings, so that external validity might be 
improved.     
 
2.8.2  Study retention rates  
 
In some studies (e.g., Amass, Kamien, and Mikulich, 2001; Metrebian et al., 
2001), approximately one-half of the subjects or more dropped out of 
treatment prior to the end of the study period.  Low retention rates can 
impact upon behavioural outcomes such as opiate use.  It is often unclear 
whether the drop-outs would have yielded higher rates of opiate use 
(because they failed to respond adequately to treatment) or lower rates 
(because they were no longer using opiates and hence were no longer in need 
of treatment).  Jain (1992: 178) noted that: 
 
“high and differential dropout rates for different  
reasons in different treatment groups can compromise 
estimation of treatment effects.  For example, the  
drugs may “cure” certain patients, and as such, they do  
not need treatment anymore (and they drop out).  In  
other cases, the drug may be a failure, and as such, the 
patients do not come back.”    
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Further, differential retention rates are often reported for two or more 
different substitute drugs that are being compared, and little is known 
about efforts that were used in attempts to improve retention.   
 
2.8.3  Reliance on self-reports and urinalysis  
 
Many studies rely heavily on self-reported drug use and similar measures.  
Although self-reports can yield valid measures of drug use, particularly 
among those in treatment, verification of these data would strengthen the 
results.  Urinalysis results as measures of illicit drug use are problematic for 
several reasons.  First, urinalysis is only able to determine whether an 
individual used a particular drug very recently, e.g., the 24-48 hour period 
prior to the collection of the urine sample.  Second, urinalysis cannot 
determine the route of administration.  Third, the amount of drug consumed 
generally cannot be identified (c.f. McLachlan-Troup, Taylor, and Trathen, 
2001).  Fourth, urinalysis cannot detect the number of times that a person 
used a particular substance in the 24-48 hour period before the urine 
sample was collected.  Johnson et al. (2000) noted that “opioid use can 
decline by 75% (for example, from four times to once daily) and still yield 
100 percent opioid-positive urine specimens.” Those authors also cautioned 
that when urinalysis is conducted too frequently, drug use can be 
overestimated because the same drug use episode can be identified on two 
or more occasions.  Fifth, instances of both false positives and false 
negatives have been identified in the literature.  Neale (1999) cited 
research by Mackie (1996) who reported that cloxacillan can produce a false 
positive for benzodiazepine in the urine and diphenhydramine can show a 
false positive for methadone.  Finally, rates of metabolism and excretion can 
influence urinalysis results of persons who consumed drugs recently (Cone 
and Dickerson, 1992). 
 
Urinalysis might be useful as a method for guiding treatment but otherwise 
the measure has little value (Barnett and Hui, 2000).  One estimate 
suggested that urinalysis in methadone programmes might reduce the 
number of drug positive urine results by a factor of 5% to 11% but those 
authors were less clear about whether urinalysis was a cost-effective 
measure in methadone treatment (Havassy and Hall, 1981).  Baker, Rounds, 
and Carson (1995) found that the percentage of opiate-positive urines was 
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approximately the same for clients who knew that urine samples would be 
collected versus those who did not know.      
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3   Possible negative implications of substitute prescribing  
 
3.1  Non-fatal overdoses, morbidity and mortality associated with substitute      
prescribing  
 
Some estimates have suggested that approximately 30 mg of methadone is 
considered to be a lethal dose for individuals with low tolerance to the drug 
(Daniels, 1997 citing information from the Edinburgh Poisons Information 
Service).  Determining the correct dosage level is critical in the initial 
stages of methadone treatment, particularly among persons who have used  
opiates infrequently (van Ameijden, Langendam, and Coutinho, 1999), e.g., 
persons recently released from jail, are using other substances, or smoke 
heroin rather than inject the drug.  Ling, Huber, and Rawson (2001: 88) 
noted that the initial seven days of methadone treatment has been 
described as a high risk period for death and emphasised the need for a 
careful “clinical review of subjects’ tolerance to methadone.”  
 
Several studies have attempted to estimate the number of methadone-
related fatalities.  In Scotland, methadone was a leading factor or was used 
in combination with other drugs in the majority of drug-related deaths 
(Cooper et al., 1999).  However, the method by which deaths are recorded by 
researchers can have implications for the research findings.  Karch and 
Stevens (2000) noted that a total of 38 methadone-related deaths occurred 
in San Francisco in 1997-1998, however, methadone toxicity was listed as a 
cause of death in only half of those deaths.      
 
Auriacombe, Franques, and Tignol (2001) compared buprenorphine- and 
methadone-related death rates in France between 1994 and 1998.  The 
authors concluded that methadone-related fatalities were at least three 
times as great as buprenorphine-related fatalities.  The authors did not 
report how they categorised deaths for which two or more drugs were 
implicated.  The study has been critically reviewed by Leavitt (2002) who 
reported that laboratory results from coroners were not used to verify the 
original data that were analysed by Auriacombe and colleagues.  The original 
authors also acknowledged that they did not have access to information on 
other drugs, pre-existing conditions among the deceased, dosage, and other 
factors.   
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Some writers have voiced concern that take-home methadone doses or 
methadone consumed without professional supervision can lead to the 
diversion of methadone that subsequently will be consumed inappropriately 
or by persons not in methadone treatment.  Although mortality data have 
shown that the number of fatal overdoses relating to opiates is higher in 
Australia compared to the United Kingdom, the number of these deaths in 
which methadone is implicated is higher in the United Kingdom (Hall, 
Lynskey, and Degenhardt, 2000).  In their review, Ling, Huber, and Rawson 
(2001) observed that this differential was perhaps due to the easier 
accessibility of methadone in the United Kingdom compared to Australia.  
Scholars have attempted to link diverted methadone with methadone 
mortalities.  For example, Valmana et al. (2000) found that methadone was 
implicated in 40 of 154 reported drug-related deaths reported in England 
and the authors observed that methadone had not been prescribed for the 
majority of these 40 persons.   
 
As noted previously, illicit use of buprenorphine has been reported in several 
countries, including England, Scotland, Bangladesh, and Australia (Agar et al., 
2001).  Buprenorphine “abuse” has had several negative implications in for 
patients in France, e.g., extreme damage to veins and skin when sublingual 
preparations of the drug are injected (Kempfer, 2000).  Further, some 
scholars have suggested that physicians in France appear to have 
contributed to overdoses resulting from polydrug use, e.g., buprenorphine 
and benzodiazepine (e.g., Reynaud et al., 1998; Tracqui, Kintz, and Ludes, 
1998).  Barrau et al. (2001) found that 25% of methadone and buprenorphine 
clients in their study (France) had consumed benzodiazepines.  Among 
benzodiazepine users, 75% of the methadone group and 80% of the 
buprenorphine group consumed benzodiazepine daily.13  Some physicians in 
France have prescribed both buprenorphine and benzodiazepines to patients 
(Seyer et al., 1998).  In a study of one region in France, researchers found 
that 43% of patients in receipt of buprenorphine had also received a 
prescription for benzodiazepine and “the daily does were often far above 
the maximum recommended dose…” (Thirion et al., 2002: 200).     
 
                                                 
13 Benzodiazepine use has been high among methadone clients in Germany (Verthein, Kalke, 
and Raschke, 1998).   
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It has since been reported that buprenorphine clients were able to obtain 
multiple prescriptions from various doctors during the same time period 
(Thirion et al., 2002).   In Germany, the government has recently introduced 
a federal register of methadone recipients in order to reduce the number of 
multiple prescriptions for the drug (Tuffs, 2001).  The south of Ireland 
implemented its register in 1993, but GPs were not required to submit 
patient details to the central register until 1999 (Keenan and Barry, 1999).   
 
3.2  Supervised consumption to prevent the diversion of substitute drugs     
 
Several authors have speculated that the supervision of methadone 
consumption might assist with preventing the diversion of methadone onto 
the illicit market, however, there is no legal requirement in England and 
Wales for doses to be consumed under supervision by a general practitioner, 
pharmacist, or other health care worker.  The Department of Health (2001) 
recently recommended that daily supervised consumption occur during the 
first three months, and possibly the first six months of treatment.  Such 
supervision works to maintain a power imbalance between patient and doctor 
or patient and pharmacist.  A policy of supervised consumption assumes that 
clients may use methadone for other means, e.g., sell or give the drug to 
others.  Moreover, methadone remains one of the few drugs for which 
supervised consumption occurs.  Vanderkloot (2001, no page listed) critiqued 
methadone maintenance polices for being “over-regulated,” characterised by 
control and power over the patient: 
 
“No other medication is so restricted that most  
patients must ingest it daily under the scrutiny of  
suspicious staff.  No other substance can be  
prescribed only under the condition that the patient  
submit to “counseling” and screens for illicit drug  
use—in perpetuity.”    
 
Robinson et al. (2000) observed that there have been very few studies that 
have focused on the extent to which drug users consume illegal methadone, 
thus we know little about diversion and how and why it occurs.14  In their own 
                                                 
14 These authors referred to three studies only, all of which were conducted in either the 
United States or Canada, e.g., Inciardi (1977), Spunt et al. (1986), and Lauzon et al. (1994).  
Two of those studies are now quite dated.        
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study of 19 attendees who frequented a needle exchange programme in New 
Zealand, nine respondents reported that “needle fixation” represented one 
factor that contributed to their use of diverted methadone.15   
 
Neale (2000) interviewed 33 drug users who had recently overdosed (non-
fatal) and had been identified by hospital accident and emergency 
departments in Glasgow and Dundee.  Methadone was implicated in 
substantially more overdoses in Dundee than in Glasgow.  Moreover, heroin 
had been consumed just prior to overdose in 16 cases (67%) from Glasgow 
but was not implicated in any of the overdoses in Dundee.  Neale (2000) 
concluded that the pattern of drugs involved in non-fatal overdoses in her 
study mirrored the mortality data from the two cities.  That is, methadone 
was far more likely to be involved in overdoses in Dundee than in Glasgow, 
and the author suggested that this difference resulted from a policy of 
supervised methadone consumption in Glasgow but not in Dundee.  Similar 
explanations have been provided with regards to differential causes of fatal 
overdoses in Glasgow and Edinburgh (Weinrich and Stuart, 2000).      
 
In reducing the extent of methadone diversion, the Department of Health 
(1999) has placed the burden on prescribers by suggesting that they develop 
methods to decrease the possibility of diversion.    
 
                                                 
15 Locally, one study found that some heroin injectors pretended to inject during 
detoxification, and one reported that he would “nod off” after doing so (McElrath, 2001).  
Other research has suggested that needle fixation can be a powerful incentive to inject 
(McBride et al., 2001).  Although little research has focused on needle fixation among 
injecting drug users, these reports indicate that the issue should be addressed in 
substitute prescribing programmes.        
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4   Substitute prescribing and dispensing practices  
 
Drug treatment agencies, general practitioners, pharmacists and other 
professionals have important roles in which to engage for substitute 
prescribing to be effective.  Moreover, patients who are prescribed 
substitute drugs for heroin dependence benefit greatly when treatment 
providers and other professionals in the management of drug users are 
involved in mutual support, share common goals, communicate effectively, 
and interact often.     
 
Seven of 16 European countries examined in a report by the European 
Monitoring Centre for Drugs and Drug Addiction (2002) allowed for GPs to 
prescribe substitute drugs to opiate users, either in conjunction with a 
specialised care centre or autonomously.  The Department of Health has 
recognised that the role of the general practitioner is critical in the 
provision of drug treatment (Department of Health, 1996; 1999), and the 
available evidence appears to support this claim.  Physicians’ offices have 
been described as effective settings in that they provide little stigma for 
patients (Gabbay, Jeffrey, and Carnwath, 2000).  Office-based settings in 
primary care also minimise the amount of contact a patient has with other 
drug users (O’Connor and Fiellin, 2000).  Other scholars have noted that 
methadone treatment offered by primary care physicians can allow for 
better treatment provision of comorbidity among drug users, as well as 
better geographic access to treatment (Weinrich and Stuart, 2000).   
Although research in the area is quite limited, studies have suggested that 
general practitioners can provide methadone treatment effectively (Macleod 
et al., 1998; Weinrich and Stuart, 2000).  Moreover, treatment provided in 
general practice has been found to be the preferred type of intervention 
among drug users (Hindler et al., 1995).   
 
Although any general practitioner in England and Wales can legally prescribe 
methadone as a treatment for opiate addiction, many GPs in those regions  
have been resistant to treat drug users (Deehan, Taylor, and Strang, 1997).  
GPs who provide care to drug users often spend more time with this 
category of patient (Gabbay, Jeffrey, and Carnwath, 2000), leaving less time 
for other patients.  Weinrich and Stuart (2000) reviewed literature and 
noted that US physicians have various concerns about introducing methadone 
treatment within the context of office-based practice.  These concerns 
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include the risk of mortality through methadone overdose, concern about 
physician responsibility in treating what is perceived to be a difficult 
clientele, and doubts about the effectiveness of treatment provided by a 
physician as opposed to specialised drug treatment clinics.      
 
Research conducted in various countries, including England, has shown that 
external support from other agencies, such as specialised drug treatment 
centres is a critical factor that can contribute to a willingness to treat drug 
users (Abouyanni et al., 2000; Groves and Strang, 2001).   
 
4.1  Shared care as a model for best practice   
 
In recent years, “shared care” has emerged as an important concept in the 
management of drug use and the delivery of drug treatment.   Citing its 1995 
report, the Department of Health (1999: 10) has defined shared care as: 
 
  “The joint participation of specialists and GPs (and  
other agencies as appropriate) in the planned delivery  
of care for patients with a drug misuse problem,  
informed by an enhanced information exchange beyond  
routine discharge and referral letters.  It may involve  
the day-to-day management by the GP of the patient’s  
medical needs in relation to his or her drug misuse.   
Such arrangements would make explicit which clinician  
was responsible for different aspects of the patient’s  
treatment and care. These may include prescribing  
substitute drugs in appropriate circumstances.”   
 
Shared care arrangements can be organised differently, depending on local 
needs.  Although support extended to GPs from specialist drug services is 
often viewed as a primary aspect of shared care programmes, Gabbay, 
Jeffrey, and Carnwath (2000) noted that specialist drug agencies also can 
benefit from the support extended by physicians.   
 
In some regions, assessment is conducted and initial dosage is provided by 
specialist agencies whose staff seek to stabilise patients.  Once patients are 
stabilised, they are then “transferred” to a GP.  Designated staff that are 
linked with specialist drug agencies liaise with and provide support to GPs in 
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primary care.  In some areas, specialised drug centres continue to deal with 
difficult, aggressive, or unstable patients (van Brussel, 1995).   
 
Such a model has operated in Edinburgh since the mid- to late-1980s, 
whereby specialist agencies offer support to clients and GPs, review 
progress, and are responsible for treating certain sub-groups of patients 
(Marsden et al., 1999).  Greenwood (n.d.) described the development and the 
role of the Community Drug Problem Service (CDPS) in Edinburgh, which 
operates under the principles of shared care.  The ideology of the Service 
has reflected harm reduction rather abstinence (Weinrich and Stuart, 
2000).   
 
Established in 1988, the CDPS serves the Lothian region and in 1995 the 
Service included 530 GPs from 133 practices (Greenwood, n.d.).  Referrals 
are made to and assessment is done initially by a community psychiatric 
nurse.  A multidisciplinary team decides the appropriate treatment and this 
decision is passed on to the GP.  If the treatment plan is acceptable to the 
GP, the client can be treated with methadone for three days through the 
CDPS.  Following central prescribing, the case is then transferred to the GP.  
The GP and the client receive support from a staff member, e.g., a nurse.  
Greenwood (n.d.) noted that that the willingness by GPs to participate in the 
scheme has been influenced greatly by the fact that the client is first 
stabilised in the CDPS setting before the case is transferred to the GP.  
The CDPS engaged in a variety of methods to further increase GP 
participation in the scheme, e.g., meetings with local GPs were held in their 
own surgeries, training on various drug-related topics was offered 
frequently, postal distribution of relevant information occurred regularly.  
In 1995, a document entitled, “Managing Drug Users in General Practice,” 
(Primary Care Facilitator Team (HIV/AIDS and Drugs), 1996) was 
distributed to all GPs in the region.16  Methadone prescribing policy requires 
urinalysis and requires that self-reported drug use be recorded in client-
kept journals.      
 
Drawing from the Lothian training material, the shared care programme in 
Tayside has assigned a keyworker to each practice.  Rome (2001) reported 
that face-to-face communication with GPs was far more beneficial than 
written correspondence that discussed a particular case.  He noted also that 
                                                 
16 The document has been revised periodically. 
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GPs in need of support were offered it as quickly as possible (e.g., within 
hours) and that liasing with GPs in this manner contributed to the immediate 
reduction of waiting lists.  The support provided by the Tayside facilitator 
varied depending on the needs of the each practice.         
 
The Glasgow Drug Problem Service was implemented in January 1994 and 
from its inception, the Glasgow Service adopted a harm-reduction 
philosophy, similar to the CDPS n Edinburgh.  The Glasgow Service reflects a 
“shared care” philosophy and has been described as a “medically led 
specialist service” (Gruer et al., 1997).   
 
In the south of Ireland, methadone can be prescribed by clinic staff or by 
GPs who have completed training.  There were 53 methadone clinics in 2000, 
the vast majority of which are located in the Dublin area (Moran et al., 
2001).   In August, 2000 there were 158 GPs who were prescribing 
methadone and 207 pharmacists who were dispensing the drug (Moran et al., 
2001).  Reflecting the principles of shared care, GPs in the south of Ireland 
and methadone clients in their care can benefit from support offered by 
methadone clinic staff.   
 
Since October 1998, GPs in the south of Ireland have been required to 
submit details of methadone patients to a central register.  Staff in 
methadone clinics supervise the methadone consumption, as do pharmacists.    
Within clinics, clients whose urines are negative for opiates over time can be 
allowed to collect take-home doses from the clinic.  Satellite clinics operate 
in some areas characterised by a low prevalence of opiate users.  Within 
these settings, methadone can be prescribed but is dispensed through 
pharmacies. 
 
4.1.1  Training GPs 
 
GPs who are involved in substitute prescribing under shared care conditions 
undergo fairly extensive training, although this review was unable to locate 
studies that have focused on process evaluations of such training.  In the 
south of Ireland, GPs who wish to prescribe methadone must participate in 
training sessions provided by the Irish College of General Practitioners 
(Moran et al., 2001).  The completion of basic training allows GPs to 
prescribe methadone only after patients have been stabilised in a methadone 
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clinic.  Completion of this training allows GPs to prescribe methadone for a 
maximum of 15 patients.  More intensive training is available for GPs who 
wish to initiate methadone treatment for patients.  A requirement of this 
training is that GPs must have worked for a minimum of one year in a 
methadone clinic.  GPs who complete this training can prescribe methadone 
for a maximum of 35 patients, although that number can be exceeded if the 
GP is in practice with two or more physicians.    
 
In Glasgow, GPs must apply to the scheme and if accepted by the physician-
led screening board they then are provided with material on methadone 
prescribing and related information.  There are special requirements for GPs 
who wish to participate in the scheme.  On-going training sessions are 
offered four times annually and occur during evening hours (Gruer et al., 
1997).  Those authors noted also that the training sessions allowed for GPs 
to interact with other GPs who were involved in the scheme.   Similar to 
policy in the south of Ireland, GPs in Glasgow can be “assigned” between 5 
and 20 methadone clients and additional fees are paid for each methadone 
patient.17    
 
The Department of Health (1999) recommended several issues pertaining to 
training in the shared care of drug users, and outlined topics to be covered 
in training sessions.  Information on the extent and nature of compliance has 
yet to emerge.  One study examined the Department of Health’s earlier 
recommendations with regards to prescribing and dispensing methadone 
(Strang and Sheridan, 1998).  Specifically, the authors examined the 
following recommendations:  1) the discontinuance of prescribed methadone 
tablets, 2) daily as opposed to less frequent dispensing, and 3) dosage levels 
to range from 50 to 100 mg per day.  Using randomly selected samples from 
1995 and 1997 surveys, the authors found that prescriptions for methadone 
tablets decreased from 12.1% to 9.5% and that daily prescriptions increased 
from 52.1% to 55.8% between 1995 and 1997.  With regards to the 
recommended daily dose of 50 to 100 mg, the authors found no change in 
this measure.  The authors concluded that there was little evidence in 
substantial compliance with the Department’s earlier recommendations.     
 
                                                 
17 Earlier reports from Amsterdam indicated that GPs in that city were responsible for 
approximately 40% of the methadone prescriptions and were limited to ten methadone 
patients (maximum) per year (van Brussel, 1995).    
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4.1.2  Effectiveness of substitute prescribing in shared care programmes    
and office-based settings     
 
Penrose-Wall, Copeland, and Harris (2000) reviewed the literature on shared 
care involving the treatment of drug use and noted the paucity of research 
on the topic.  Moreover, the limited research has been largely descriptive.  
For example, a study of 89 health authorities in England, Wales and Scotland 
revealed that 26 had developed protocols regarding shared care for the 
treatment of drug use (Gerada and Tighe, 1999).  Most agencies responding 
to the survey had developed informal protocols only.  Of those agencies 
which had developed formal protocols, approximately one-third of the 
agencies had arrangements with general practitioners.  The authors noted 
that the role of the GP in these arrangements most often was limited to 
prescribing.  These findings run counter to the guidelines issued by the 
Department of Health (1999: 12) which suggested that “the level of 
specialist support available to the GP and Primary Health Care Team, ease of 
access to this support, and the willingness and flexibility of all parties 
involved in shared to work together” are all fundamental in the effectiveness 
of shared care models.  However, it is possible that advances have been 
made since Gerada and Tighe published their report.  More recent reports 
from Scotland indicated that some aspect of shared care in the treatment 
of drug users was operating among 20 of 22 Drug Action Teams in that 
region (Gray, 2001).      
 
Research that has examined the effectiveness of methadone treatment in 
general practice settings has shown promising results.  O’Connor et al. (1998) 
compared the effectiveness of buprenorphine in two settings: a primary care 
office and a methadone maintenance clinic.  The rate of treatment retention 
was higher among clients in the office-based setting as was the rate of 
opiate negative urine samples.   
 
In the United Kingdom, largely England and Wales, Gossop et al. (1999) 
examined six-month outcome data for 452 opiate “addicts” who had received 
methadone treatment from either a general practice or a specialist drug 
clinic.  Comparing the two treatment settings, the authors observed similar 
improvements since baseline in the areas of health, social functioning, and 
drug-related problems.       
  47
The shared scheme in Glasgow, with its supervised daily consumption of 
methadone, formed the basis of a recent study by Hutchinson et al. (2000).  
Using baseline data from 204 IDU methadone clients in Glasgow, 
researchers examined changes in behaviours at six and 12 months.  Follow-up 
rates were 73% (six months) and 58% (12 months).  A total of 29% of the 
sample had received methadone treatment during the entire 12-month 
period.  The authors noted significant reductions in daily opiate injecting 
(self-reported data), drug expenditures, involvement in acquisitive crimes, 
and overdoses at both 6- and 12-month follow-up interviews.     
 
In Edinburgh, supervision by the shared care team (in particular, the 
involvement of nursing staff) was deemed to have contributed to the very 
low mortality rates among methadone clients (Macleod, Whittaker, and 
Robertson, 1998).    
 
4.1.3  The role of the pharmacist in shared care arrangements 
 
Shared care involving pharmacists has been much more prevalent in various 
parts of Scotland than in England and Wales and in the south of Ireland.   
In Glasgow, a large proportion of prescribed methadone is consumed under 
the supervision of pharmacists, and this policy was introduced to reduce the 
likelihood of diverted methadone.  Gruer et al. (1997) reported that in the 
mid-1990s, approximately 91% of methadone patients consumed methadone 
under pharmacist supervision even though pharmacists are not legally 
required to do so.  Gruer et al. (1997) cited research from England and 
Wales that reported a much lower figure (i.e., approximately one-third) of 
pharmacist supervision in those regions.  The review by Luger et al. (2000) 
confirmed that pharmacist supervision of methadone consumption is far 
more prevalent in some regions (e.g., Glasgow) than in others (e.g., London).    
     
Roberts et al. (1998) noted that guidelines issued by the Greater Glasgow 
Health Board included the recommendation that patients undergo supervised 
consumption of methadone during the first year of methadone treatment 
and that this policy should continue unless the GP strongly believes that the 
prescribed dose will be taken as intended.  In some regions, take-home doses 
can be arranged for collection for clients who progress well in treatment.   
 
  48
Pharmacist supervision of methadone consumption was endorsed by the local 
pharmaceutical body in greater Glasgow (Gruer et al., 1997).  Additional fees 
are paid to pharmacists who supervise methadone taking, and who report 
information on dispensing, maintain records for auditing purposes, and 
participate in training.   
 
Roberts et al. (1998) estimated that over one million supervised doses of 
methadone had been administered in Glasgow between 1994 and early 1998.  
Those authors also reported that as of early 1998, 89% of Glasgow 
pharmacies were involved in methadone dispensing and that most pharmacies 
were open six days per week.       
 
In the Lothian region of Scotland, Greenwood (1997) noted that several 
methadone-related deaths in that area appeared to have occurred in people 
who were not in receipt of methadone treatment.  This information led to a 
discussion of whether the region should adopt a policy of supervised 
methadone consumption.  Supervised consumption now occurs in Edinburgh 
but the practice still occurs less frequently than in Glasgow.  In the south of 
Ireland, the prescription must note whether the methadone is to be 
consumed in the presence of the pharmacist (Moran et al., 2001).   
   
Some research has found that pharmacists have expressed a willingness to 
supervise the consumption of methadone; however, other pharmacists noted 
that they lacked training with regards to dealing with “difficult situations,” 
e.g., patients who become aggressive in pharmacy settings (Sheridan et al., 
1996).   
 
Research conducted in London (Luger et al. 2000) found that the supervision 
of methadone consumption took approximately five minutes or less (although 
the amount of time spent on completing forms was not measured).  That 
study also showed that pharmacists generally were not concerned that 
supervising methadone consumption would negatively affect their business.   
Pharmacists who participated in the study reported having had fewer 
problems with patients whose methadone was supervised compared to other 
drug users who frequented the pharmacy.  The study also found that 
relationships between patients and pharmacists improved over time, that is 
the daily contact between patient and pharmacist led to “trust and mutual 
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respect” and daily contact meant that the pharmacist was in a better 
position to advise about other health issues.   
 
Research has investigated methadone clients’ attitudes about collecting 
methadone prescriptions from pharmacies and supervised consumption in 
those premises.  An Australian study found that many methadone clients  
voiced concern about the public visibility of collecting prescriptions in 
pharmacy settings as well as discrimination by pharmacists (Ezard et al., 
1999).  Luger et al. (2000) found that methadone clients were in general 
quite satisfied with the pharmacist-based practice, however, the primary 
areas of concern among clients focused on 1) the lack of privacy during 
methadone consumption, and 2) pharmacist-led decisions about the timing of 
dispensing.     
 
Neale’s study of drug users in receipt of substitute treatment in Scotland 
(1999) found that respondents held mixed views of supervised methadone 
consumption, although most respondents favoured supervision.  For instance, 
some respondents felt that supervised consumption in pharmacy settings 
provided them with a safe environment.  Alternatively, several other 
respondents preferred to not be supervised and the major reason for this 
decision was the perceived lack of privacy in pharmacy settings.  Supervised 
consumption produced feelings of embarrassment and degradation among 
these clients.      
 
To address the issue of privacy, some pharmacists have designated special 
private places within the pharmacy where supervised consumption occurs  
(Gruer et al., 1997).  The perception of “privacy” can differ between 
pharmacists and patients.  For example, one study found that pharmacists 
reported that they practiced methods to create a sense of privacy during 
methadone consumption.  However, the majority of client respondents in 
that study voiced concern about privacy, noting how they consumed the 
liquid quickly to avoid embarrassment in front of other customers (Luger et 
al., 2000).   
 
One disadvantage of supervised consumption is that the policy requires 
methadone clients to travel to a particular pharmacy on a daily basis.   
Clients have reported that daily dosing interferes greatly with other life 
activities (Ling, Rawson, and Compton, 1994).  Neale’s qualitative study of 96 
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individuals from Scotland who were in receipt of substitute drugs found that 
most respondents appeared to be “dissatisfied” with the requirement of 
daily trips to the pharmacy because of travel costs, or because the daily 
trips interfered with other lifestyle activities, e.g., work or study, travel, 
holiday plans.  Daily dosage consumed outside the home might be one factor 
that affects treatment retention, although little research has examined this 
issue with respect to methadone (c.f. Rhoades et al., 1998).       
 
Take-home doses diminish the need for daily travel to and from pharmacies.  
Illegal or unsafe use of methadone is alleged to result from legitimate 
sources, i.e., unsupervised consumption of methadone, take-home doses 
(Farrell et al., 1998).  However, few studies have investigated the source of 
“street” methadone.  Moreover, take-home doses might allow for greater 
trust and rapport between client and clinician.  If take-home doses are 
allowed, clients need to be instructed on proper storage.  In one study from 
Dublin, approximately one-fourth of opiate users who were permitted take-
home doses had used baby bottles to measure methadone (Harkin, Quinn, 
and Bradley, 1999). 
 
Programmes should recognise the difficulties that clients experience when 
organising visits to and from pharmacies.  A review of the literature has 
failed to identify methods that strike a balance between meeting client 
needs with respect to daily dosing and preventing methadone from being 
leaked to illicit drug markets.       
 
4.1.4  Training pharmacists    
 
In shared care arrangements, the training of pharmacists is just as 
important as the training of GPs.  In Glasgow, accredited training for 
pharmacists focuses on the areas of drug use and related issues.  Meetings 
are organised and attended by both pharmacists and GPs who are involved 
with the dispensing and prescribing of methadone (Roberts et al., 1998).    
Information and training topics are also available through distance learning.      
Matheson, Bond and Hickey (1999) suggested that training should 
incorporate pharmacists’ negative attitudes towards drug users so that the 
provision of services can be improved and additional pharmacists will be 
motivated to become involved in the management of drug users.   
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5   Further considerations 
 
5.1  Costs of substitute prescribing 
 
In their review of various literature, Rosenheck and Kosten (2001) observed 
that the introduction of opiate substitution could result in lowered or 
delayed relapse, lowered medical costs such as HIV, Hepatitis C, and other 
infectious disease, as well as resulting in reduced expenditures for the 
criminal justice system.  Those authors compared projected costs of 
buprenorphine/naloxone and methadone maintenance in the United States.  
Slightly higher costs were associated with methadone although the authors 
cautioned that their analysis made several assumptions about hypothetical 
factors that could affect costs, e.g., fewer counselling sessions among 
buprenorphine clients.  Also, in the US, methadone is not prescribed in 
office settings; rather, methadone maintenance is available through selected 
clinics.   For example, the authors noted that “patient time and travel costs” 
would be higher for methadone maintenance in part because of travel time 
to and from those few methadone clinics.  In contrast, buprenorphine  
administered in primary care settings would reduce travel time.  
Considerably less is known about cost comparisons in the United Kingdom.   
 
5.2  Substitute prescribing and pregnancy 
 
A report issued by the Lindesmith Center-Drug Policy Foundation (2000) 
concluded that detoxification from heroin can produce miscarriage and 
premature birth.  Methadone can be used safely during pregnancy, however, 
the risk of miscarriage is increased if methadone dosage levels are reduced 
during the first trimester of pregnancy.  The report also indicated that 
methadone has been shown to be safe for breastfed babies.   
 
A study of methadone treatment coupled with monetary vouchers for 
treatment attendance and cocaine-negative urine samples found that 
attendance was significantly higher for subjects who were assigned to the 
voucher incentive group compared to controls (Jones et al., 2001).  
Moreover, illicit drug use as measured by urinalysis was lower among 
participants in the voucher incentive group than in the control group during 
the first week of outpatient treatment.   
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Considerably less research has investigated the use of buprenorphine among 
pregnant opiate-dependent women.  The few studies that have been 
conducted (e.g., Fischer et al., 1998) have been based on small sample sizes 
and possibly confounded by the effect of other interventions, e.g., 
participation in comprehensive treatment.   
 
5.3  Parenting and substitute prescribing  
 
Dependent heroin users with children have special needs and programmes 
need to recognise and respond effectively to these needs.  With respect to 
this issue, female dependent users are likely to be affected than males.  For 
example, data from the US have shown that females in methadone 
treatment have more dependent children than males (Rowan-Szal et al., 
2000; Wechsberg et al., 1998).  Women methadone clients who seek 
employment outside the home have reported having experienced problems 
associated with finding and paying for adequate child care.  A qualitative 
study conducted in Dublin suggested that disproportionately more women 
than men drug users reported that the lack of adequate childcare was a 
barrier to effective treatment, as well as a barrier to educational and 
employment possibilities (Moran, 1999).  Only nine of the 45 drug treatment 
centres in the region provided childcare through crèche facilities (Moran, 
1999).  In some treatment settings, childcare was provided through “drop in” 
services whereby children were cared for as parents sought treatment.  
Although the nature of the study precluded generalisations to the wider 
population of opiate-dependent parents, the availability of childcare 
appeared to contribute to more amenable treatment options for women.  The 
study identified the need for two types of childcare for drug users: 1) 
facilities that offered childcare for the entire day, and 2) “drop in” 
facilities to be used as needed.     
 
Substitute prescribing programmes that do not permit take-home doses 
could pose major problems for parents.  Clients with very young children will 
have to either arrange and perhaps pay for childcare while they travel to 
and from pharmacies or have the children accompany them.  Parents with 
school-age children might find that visits to pharmacies conflict with 
collection from schools.  In-patient treatment, even for short stays involving 
detoxification may not be an option for primary caregivers.  It is 
unacceptable that some parents must in effect choose between participating 
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in drug treatment and managing childcare.  Programmes must develop “family 
friendly” methods that encourage parents to participate in drug treatment.  
If not, substitute prescribing programmes will disproportionately exclude 
parents of young and school-age children.   
 
5.4  Methadone maintenance in prison settings 
 
Methadone clients who are detained by police or incarcerated in prison are 
of special concern.  Of 276 methadone clients imprisoned during a 12-month 
period in Scotland, only 4% of cases involved subsequent communication 
between the prison doctor and the client’s general practitioner (Gruer and 
Macleod, 1997).  Methadone is available for detoxification or as a treatment 
intervention in selected countries only.  In Australia, researchers have found 
that methadone maintenance reduces injecting drug use in prison (Dolan, 
Hall, and Wodak, 1996).  According to 1999 government estimates, between 
1,200 and 1,500 prisoners in Mountjoy Prison (Dublin) were undergoing 
methadone detoxification annually (Department of Justice, Equality and Law 
Reform, 1999).  Very few prisoners, however, were afforded methadone 
maintenance during their incarceration.  Recently released prisoners appear 




6   Recommendations 
 
6.1 It is recommended that methadone maintenance be made available 
as a treatment option to individuals dependent on heroin.   
 
The review of the cumulative evidence suggests that methadone 
treatment can increase treatment retention, reduce subsequent 
opiate use, and reduce drug-related criminal activity (pages 7-15).  
The evidence to date is less conclusive about the effects of 
methadone treatment on risk behaviours for HIV infection, 
particularly sexual risk behaviours.  However, the evidence from some 
countries suggests that HIV seroprevalence rates are lower for 
methadone clients compared to other problem opiate users who have 
not undergone methadone treatment (pages 9-10).   
 
Regarding subsequent heroin use and drug-related criminal activity, 
the evidence suggests that methadone treatment is most effective in 
programmes that are based on the philosophy of maintenance rather 
than abstinence or reduction (pages 7-8; 12).  Higher treatment 
retention rates have been associated with maintenance programmes 
compared to reduction programmes.      
 
6.2 It is recommended that a maximum length of time in methadone 
treatment should not be imposed.   
 
The primary goal of such intervention should be to retain individuals in 
treatment.  Reduction programmes should be an option as well, but 
this decision should rest with the client after balanced advice is 
provided by professionals.  Moreover, it is important that methadone 
reduction does not become a “de facto” intervention, i.e., one that is 
applied universally within any particular treatment agency or by any 
physician, without regard to client need.   
 
6.3 It is recommended that the DHSSPS does not implement a central 
register that would collect information on persons in receipt of 
methadone.   
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Qualitative research with largely Belfast heroin injectors found that 
many heroin users were quite suspicious of official drug data that 
included personal information (McElrath, 2001).  In that study, heroin 
users perceived that they could not be guaranteed complete 
confidentiality with respect to their drug user identities.  In turn, 
some individuals avoided contact with GPs and other treatment 
providers.   
 
It is recognised, however, that some type of monitoring is necessary 
in order to reduce the possibility of double prescribing by two or 
more physicians.  Creative strategies should be developed that would 
diminish double prescribing while at the same time, would not deter 
persons coming forward for treatment.  The Addicts Index and Drug 
Misuse Database are already in place and might represent two 
methods for monitoring persons in receipt of methadone.      
 
6.4 Liquid rather than injectable methadone should be used for 
methadone maintenance.   
 
Most of the research has examined the effectiveness of oral 
methadone so that considerably less is known about the effectiveness 
of injectable methadone (page 11).  Although prescribing injectable 
methadone might address needle fixation, injection risk behaviours 
might still present problems.   Injectable methadone might be an 
option at a later date, but this decision should be guided by the 
professional opinions of treatment staff and physicians in N. Ireland, 
as well as subsequent research findings.  For example, a study on 
injectable versus oral methadone is currently underway in Scotland.  
Results from that study might be quite useful to drug policy makers in 
N. Ireland.   
 
6.5 Methadone should be the preferred substitute drug for heroin  
dependence, however, clinical discretion with regards to the choice 
of substitute drug should be acknowledged.   
 
The Department of Health permits the use of buprenorphine as a 
treatment for opiate dependence, thus clinicians who prescribe 
buprenorphine are acting in accordance with guidelines.  However, 
  57
clinicians should be aware that in comparison to methadone, 
considerably less is known about buprenorphine as a treatment for 
opiate dependence.  In particular, long-term studies of buprenorphine 
in comparison to methadone have yet to be published so that we know 
little about long-term effects of such treatment (page 18).  Studies 
that investigate the relationship between buprenorphine treatment 
and subsequent drug-related criminal activity also are lacking (page 
18).       
 
The Advisory Board overseeing this report suggested that this 
researcher contact the five consultant psychiatrists (CPs) in N. 
Ireland who would likely be involved if substitute prescribing were 
implemented, in order to ascertain their views on methadone and 
buprenorphine (Subutex).  From those discussions, three of five CPs 
have used methadone sparingly, whereas two have had more 
experience with patients in receipt of methadone.  Three of five had 
provided buprenorphine (i.e., Subutex) to patients undergoing either 
detoxification or for longer-term use.    
 
CP 1 prefers Subutex to methadone for long-term (i.e., reduction or 
maintenance) use, citing its safety record.  CP 1 also notes that 
Subutex works effectively for patients undergoing detoxification, was 
in favour of some type of substitute prescribing but did not appear to 
have a preference for either methadone or Subutex.  CP 2 does not 
oppose methadone but prefers Subutex because of the latter’s 
“greater safety record.”  CP 2 acknowledges the possibility of 
diverted Subutex and suggests the combined buprenorphine/naloxone 
might work well here (but see pages 16-17), if approved by the DOH.  
Overall, CP 2 states that the choice between Subutex and methadone 
should be a “clinically driven” decision and that with time, the 
problems and successes of each substitute drug will emerge locally.   
CP 2 notes also that Subutex might be more successful than 
methadone during detoxification.  CP 1 and CP 2 suggest that Subutex 
might be more effective with younger persons who have used heroin 
for shorter lengths of time than more experienced, older persons. 
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Although CP 3 has worked with very few persons who are dependent 
on heroin, s/he prefers Subutex to methadone, citing the safety 
record of Subutex.    
 
CP 4 has treated patients with methadone and with Subutex.  S/he 
also reports that patients generally have had positive outcomes with 
either of these substances.  CP 4 reports that the goal is to match 
patients’ expectations with what a particular substitute drug can 
offer, thereby taking into account users’ opinions when deciding on 
which substitute drug to prescribe.    
 
CP 5 reports that methadone maintenance should never be 
implemented in N. Ireland.  CP 5 notes the “negative aspects of 
methadone maintenance” (e.g., dependence on methadone) and that 
heroin use in N. Ireland would increase with the availability of 
methadone maintenance.  CP 5 has treated some heroin users here, 
and in the last six months, has noted a small increase in the number of 
people seeking treatment for heroin dependence.  CP 5 states that 
most patients treated in the site move to or return to N. Ireland from 
elsewhere, and do so because they wish to abstain completely and do 
not wish to reside in settings in which heroin and methadone are 
available.  The site in which s/he works operates under an abstinence 
only policy.  S/he prefers to provide inpatient detox with Lofexidine 
and if needed, prescribes Naltrexone for a period of six months to 
one year.  CP 5 might, however, be in favour of Subutex in the long-
term, but in general CP 5 does not advocate maintenance.      
 
These discussions indicate that some consultant psychiatrists have 
prescribed buprenorphine for persons dependent on heroin in N. 
Ireland.  Some CPs mentioned the safety record of Subutex, however, 
none indicated that the long-term effects of Subutex have yet to be 
examined.  Nor did they mention the lack of research concerning the 
relationship between Subutex maintenance and subsequent drug-
related criminal activity (nor were they asked about these 
drawbacks).  Written guidance about the possible limitations of 
buprenorphine should be distributed to CPs and other professionals 
who will be involved in prescribing substitute drugs to persons 
dependent on opiates.     
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6.6 At present, heroin maintenance should not be offered as a 
treatment option.  
 
Research into the effectiveness of heroin maintenance suggests that 
the treatment can reduce criminal activity, but the evidence is less 
clear about the effects of heroin maintenance on other outcomes, e.g., 
relapse (pages 20-21).  Considerably more research is needed in this 
area before heroin maintenance can be offered as a treatment for 
persons dependent on heroin.  A review of findings from current 
studies being conducted in the Netherlands, and planned clinical 
(heroin maintenance) trials in Germany might be relevant for N. 
Ireland in the future. 
 
6.7 Diagnosis and assessment of drug dependence should be guided by 
the recommendations issued by the Department of Health as well 
as experts from Glasgow and Edinburgh.   
 
The Department of Health (1999: 19-21) has outlined those areas that 
might be covered in the diagnosis of drug dependence and assessment.  
This information should be reviewed carefully by clinicians and other 
professionals who will be involved in a programme of substitute 
prescribing.  Moreover, it is important to obtain up-to-date 
information with respect to diagnosis and assessment.  Discussion with 
experts from Glasgow or Edinburgh should be held with regards to 
additional issues that might be important for assessing opiate or 
heroin dependence.  Methadone will not be effective for all opiate-
dependent persons, and further, some clients will not opt for 
methadone.  Thus, assessment is a critical stage of the treatment 
process. 
 
6.8 It is important that initial dosage levels be monitored very closely.  
and that the DHSSPS implement a flexible methadone dosing 
policy.   
 
Decisions about initial dosage levels are critical.  Initial doses should 
seek to reduce craving for heroin and prevent withdrawal.  Sedation 
effects should be avoided.  In the majority of cases, initial doses of 
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20 to 30 mg per day are considered to be in the safe range (Payte and 
Khuri, 1993), however, the Department of Health (1999: 46) 
recommended an initial dose of 25 to 40 mg per day if tolerance is 
high, and between 10 to 20 mg per day if tolerance is low or unknown.  
Lower initial doses of methadone might be more suitable for users 
who smoke or chase the drug, rather than inject (Payte and Khuri, 
1993).  During induction in particular, tolerance to methadone should 
be monitored frequently.  Some information suggests that patients 
presenting for methadone treatment might misrepresent their opiate 
history in order to obtain higher doses of methadone (Payte, 1999).  
Monitoring methadone plasma levels could assist with dosing decisions 
(Department of Health, 1999).  Women patients should undergo 
pregnancy testing before methadone is provided.  Persons recently 
released from prison or similar setting and persons who have not used 
heroin for some time should generally be given lower doses.  Following 
the first dose, an additional dose of approximately 10 mg can be 
provided 3-4 hours later if cravings continue and withdrawal 
symptoms persist (Payte and Khuri, 1993).  The Department of Health 
(1999) recommended that second doses can be a maximum of 30 mg, 
however, subsequent doses in outpatient settings should not exceed 5 
to 10 mg per day.  Additionally, the total increase during the first 
week “should not usually exceed 30 mg above the starting day’s dose” 
(Department of Health, 1999: 46).  Stabilisation should begin to occur 
between 4 and 10 days after the initial dose (Payte and Khuri, 1993).  
It is recommended that there is an urgent need for regular and 
consistent follow-up.  Once a patient is stabilised, changes to dosage 
levels can be made particularly in times of stress, anxiety or 
depression (Payte and Khuri, 1993).   Methadone clients must be 
provided with educational information about methadone, including 
methods to avoid overdose and dangers associated with drug 
interactions.  Clients should be made aware of initial dosage levels and 
dosage changes.  For clients who wish to withdraw from methadone, 
decreases in doses should not exceed 10% of the stabilised dose and 
subsequent dose reductions should occur between 10 and 14 days later 
(Payte and Khuri, 1993).    
 
The impact of methadone dosage levels has been well-researched and 
the cumulative evidence suggests that high-dose methadone  
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contributes significantly to improved treatment retention as well as 
reduced risk for relapse (pages 11-15).  Further, the research 
suggests that flexible dosing policies produce more favourable 
outcomes (pages 12-13).  Some clients will feel comfortable on 50 mg 
of methadone or less per day whereas others will require considerably 
higher doses.  Dosing decisions must consider the extent of 
dependence, the intensity of cravings and withdrawal symptoms, the 
frequency of opiate use, recent opiate use, other drug use, and the 
purity of heroin within a particular region.  Monitoring methadone 
plasma levels can assist with dosing decisions.  Based on the evidence, 
it is recommended that methadone treatment programmes incorporate 
flexible dosing policies.   
 
6.9 Prescribers must be provided with very detailed information on 
drug interactions.   
 
The Lindesmith Center-Drug Policy Foundation (2000: 21) reported 
that methadone dosage may need to be increased if the client is using 
any one of the following drugs:  Carbamazepin (Tegretol), Phenytoin 
(Dilantin), Neverapine (Virammune), Rifampin, and Ritonavir (Norvir).  
These drugs reduce the effect of methadone because the drug 
interactions “cause the liver to metabolise methadone more quickly.”  
The authors also note that use of other drugs may increase the 
effect of methadone, whereas other interactions can produce 
withdrawal.  Certain antidepressants can increase methadone 
concentrations in the body whereas benzodiazepines and St. John’s 
Wort can produce adverse side effects when used with methadone 
(Goodman, Jones, and Glassman, 2001).    Alcohol, barbiturates and 
other sedatives may increase the metabolism of the methadone (Payte 
and Khuri, 1993).  Gourevitch and Friedland (2000) reported that the 
interaction between methadone and AZT and other medications used 
to treat HIV infection can produce withdrawal symptoms in patients.  
The authors recommended that with some medications, methadone 
doses should be increased in small increments at a time, and health 
care providers must be knowledgeable about the interactions between 
methadone and the various substances used to treat HIV infection.  
Other possible drug interactions are described in the report issued by 
the Department of Health (1999).  It is recommended that 
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prescribers be fully aware of drugs that can interact with methadone.  
The Department of Health (1999) provides guidance on this matter, 
but their list of drug interactions is by no means exhaustive. 
 
6.10 Where possible, it is recommended that shared care protocols for 
the treatment of heroin dependence be implemented.   
 
Shared care models show great promise, however, research into the 
effectiveness of shared care is limited.  Still though, the few studies 
that have examined the effectiveness of shared care or practice-
based treatment have reported favourable results (pages 42-44).  
Implementation of such models require considerable planning and a co-
ordinated effort involving several professionals.  It is important to 
identify creative methods that will contribute to participation among 
physicians, pharmacists, and other professionals.  Initial and on-going 
training as well as an organised support network are critical 
components of successful shared care models. 
 
Following the recommendation by the Department of Health (1999: 
12), guidelines should reflect “national” policy [or in this instance, N. 
Ireland policy), but at the same time “be locally determined.”  N. 
Ireland guidelines should allow for flexibility with respect to problems 
and issues that emerge locally.  Shared care operates under the 
principles of frequent and effective communication between and 
among professionals.  The development of the guidelines should involve 
all participants, e.g., general practitioners, pharmacists, drug workers, 
voluntary and statutory agencies.  It might also be useful to solicit 
the opinions of users themselves.  User input into several areas of 
drug policy appears to be lacking.  Topical areas to be included in local 
guidelines should be drawn from the Department of Health (1999: 13), 
although additional topics should be addressed if pertinent to the 
locality.  Roberts et al. (1998: 193) suggested that regions that seek 
to implement a shared care model of drug treatment involving 
methadone need the following:  1) good leadership within a team 
approach, 2) clearly defined roles and excellent communication 
between professionals, 3) the use of contracts outlining expectations 
of the team members. 
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The Department of Health (1999: 14) recommended the establishment 
of a “shared care monitoring group,” comprised of representatives 
from various sectors.  The monitoring group should have responsibility 
to “approve local agreements and protocols, review training needs, 
clarify performance indicators and monitor the delivery and 
effectiveness of shared care service provision in the area.”  It is 
recommended that monitoring groups be established within various 
regions of N. Ireland.   
 
6.11 Persons who are dependent on heroin should be provided with 
various methods for accessing substitute drugs.   
 
In some instances, specialised drug treatment sites should provide 
assessment, prescribing as well as the supervision of methadone 
consumption.  In other instances, stabilised clients should be 
transferred to GPs, with supervised consumption provided by 
pharmacists.  Other individuals might benefit most when assessed and 
treated solely by the GP (although the monitoring of detoxification 
might be difficult in physicians’ offices).  For instance, some 
individuals might have considerable concerns about confidentiality, 
given their physical presence in a drug treatment setting.  
Additionally, other persons who desire treatment might be 
disadvantaged because of the proximity between their residences and 
the locations of drug treatment sites.  We must assume that there 
are people dependent on heroin in N. Ireland who will not seek 
assistance from a drug treatment agency but might consult a GP.  It is 
important that heroin-dependent persons are provided with different 
options for accessing treatment.  The general practitioner is often 
the “first point of contact” for young drug users in particular 
(Department of Health, 1999: 11).  In addition to prescribing 
methadone, GPs can also treat or refer for psychological and physical 
morbidity and drug-related illnesses.  They can test for HIV 
antibodies, and test for Hepatitis B and C viruses, and immunise where 
necessary.  GPs can also distribute material with regards to safer 
injecting, needle exchange, condom use, and make referrals to 
specialist drug clinics, psychiatrists, social workers, drug services 
(e.g., Narcotics Anonymous). 
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Shared care options might include facilitator teams that include 
trained drug workers or public health nurses who can assist physicians 
with various patients.  There should be written agreement with 
regards to which shared care team member will be responsible for co-
ordinating the treatment plan and delivery.  “Key workers” are 
appointed for a number of clients in various parts of Scotland 
(Effective Interventions Unit, 2001).  All professionals involved in the 
treatment of heroin dependence should be required to undergo initial 
and subsequent training.  Training might be provided through 
contractual arrangements with professional staff from Scotland who 
have worked in similar schemes.  Staff involved with the programme in 
Edinburgh have described methods for encouraging physician 
participation.  Weinrich and Stuart (2000) concluded that physician 
leadership is a critical factor for the establishment of successful 
shared care programmes to assist drug users.   Additional creative 
strategies might be needed in N. Ireland.  GPs and pharmacists should 
be provided with on-going support from drug service agencies.  
Support should be provided on demand, depending on the needs of the 
individual physician.  Updated information on methadone treatment 
should be distributed frequently to GPs, pharmacists and drug 
workers who are involved in methadone treatment.     
 
6.12 It is recommended that methadone consumption be supervised for 
the first six months of treatment, and perhaps longer for some 
clients.  
 
It is critical that we aim to reduce the likelihood of methadone-
related deaths.  Although some researchers have argued that the risk 
of fatal overdoses from heroin are reduced among methadone clients 
(page 8), it is equally important to diminish the risk of methadone-
related fatalities.  A report issued by the Advisory Council on the 
Misuse of Drugs (2000: 63) states that: 
 
“It could be argued that there may be an inverse  
relationship between the number of heroin and  
methadone-related deaths, with reductions in heroin  
overdose deaths partially offset by an increase in  
methadone-related overdose deaths.  If this is true  
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then the answer should be to find a system which  
does not lose the benefit of reducing heroin-related  
deaths by increasing methadone-related deaths, but  
which has appropriate prescribing controls built in, so  
as to obviate the downside.” 
 
The literature reviewed herein found that other scholars have 
suggested that a policy of supervised consumption appears to be 
linked to fewer methadone-related fatalities (page 40).   
Recommendation 6.12 is consistent with the guidance offered by the  
Advisory Council on the Misuse of Drugs (2000).  This recommendation 
is based on the premise that supervised consumption will reduce the 
likelihood of methadone mortality.  Agar et al. (2001: 76) suggested 
that “an effective maintenance drug will always be interesting to the 
streets as well,” and supervised consumption is thought to prevent 
diversion.  In fact, diverted methadone has not been well-researched 
(pages 39-40) and in fact, we may have no way of knowing whether the 
methadone associated with a drug-related death indeed derived from 
a legitimate medical source in N. Ireland.   
 
It is important to note that a policy of supervised consumption might 
lead clients to terminate treatment or avoid it altogether.  This issue 
should be monitored closely.  Following six months of treatment, take-
home doses should be permitted for clients who have shown to be 
actively engaged in other programme activities and whose urinalyses 
results have been negative for opiates.  Sunday and holiday collections 
will be problematic when take-home doses are not permitted.    
Supervised consumption of methadone should occur in pharmacies or 
in specialised treatment sites.  Pharmacists must provide privacy for 
supervised consumption.  However, some clients, e.g., pregnant women, 
parents with young children, will have difficulty arranging for the 
collection of daily doses of methadone.  In these instances, a member 
of the shared care team should visit the homes of clients so that 
methadone treatment can be continued.  Two of the CPs and two CAT 
staff members suggest a flexible policy about supervised consumption, 
recognising that supervision by pharmacists might be impossible to 
implement on Sundays, holidays, etc.  In these instances, these 
individuals report that take-home doses should be permitted.  One 
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CAT staff member reports that take-home doses are permitted one 
day per week (i.e., Sundays).               
 
With regards to a time period of supervised consumption, CP 2 refers 
to the guidelines developed by the DOH (i.e., 3 months) and by the 
Advisory Council on the Misuse of Drugs (i.e., 6 months), but notes 
that flexibility is needed.  For example, CP 2 notes that women in the 
late–stage of pregnancy might have difficulties collecting daily 
(methadone) and thrice-weekly (Subutex).  Take-home doses should 
be considered for these patients.  CP 2 also notes that individuals 
residing in rural settings also experience problems with daily dosing.  
A staff member from one Community Addiction Team reports that for 
at least the past year, nearly all clients have been required to 
participate in supervised consumption of methadone or Subutex.  One 
exception was made for a client who travelled a great distance to the 
programme site.  However, this client has actively engaged in 
counselling and other program components, and urine specimens for 
this client have been consistently “clean.”  CP 4 reports that take –
home doses are permitted on days when pharmacies are closed, e.g., 
Sundays, bank holidays, or when clients are on holiday.    
 
6.13 Implement a monitoring system for tracking methadone-related 
deaths. 
   
In order to monitor methadone-related deaths following the 
implementation of substitute prescribing, it is important to collect 
baseline mortality data.  Recorded deaths where methadone is listed 
as a primary or secondary cause of death should be noted for the five 
years prior to the implementation of substitute prescribing.  It is 
important to collect information on how deaths are recorded by 
coroners and to note any possible sources of error in these mortality 
data.    
  
6.14 Urinalysis should be used only as a method to monitor treatment 
progress and as a tool to assist with the prevention of overdose.  
 
Urinalysis can produce both false positives and false negatives and is 
only able to detect very recent drug use.  The cost-effectiveness of 
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urinalysis has been questioned (pages 34-35), and one study found no 
differences in urinalysis results between clients who were informed of 
checks prior to the collection of urine samples and clients who were 
not informed (pages 34-35).  Urinalysis should be conducted on a 
periodic and random basis, however, urines that are positive for 
opiates and other drugs should not result in treatment termination.   
 
6.15 The number of persons in receipt of methadone and other 
substitute drugs for maintenance should be monitored closely.    
 
Hartnoll (1999) estimated that substitute prescribing rarely is able to 
reach more than 50% of problem opiate users, even when a range of 
these interventions are available.  Assuming a point estimate of 828 
problem heroin users during 1 November 2000 to 31 October 2001 for 
N. Ireland (McElrath, 2002), it is estimated that the maximum 
number of different people taking part in substitute prescribing 
during a given year would be 414.  If that point estimate has increased 
since that study was conducted, we might expect a similar increase in 
the estimate.  Low numbers of persons in receipt of substitute drugs 
could indicate that the treatment or programme components are not 
being implemented correctly.     
 
6.16 Develop outreach teams within various regions in N. Ireland. 
 
A recent study from N. Ireland found that between 48 and 64% of 
problem heroin users had not been in treatment during the 12-month 
period, 1 November 2000 to 31 October 2001 (McElrath, 2002).  It is 
important that we improve participation rates in various forms of drug 
treatment in N. Ireland.  Moreover, relapse after treatment is a 
matter of concern.  Several studies show that a number of clients 
continue to use opiates during methadone treatment or do so after 
treatment has ended.  There is a need for the development of 
creative strategies that would reduce the probability of relapse.  In 
order to improve treatment participation and to prevent relapse, it is 
recommended that outreach workers be assigned at local levels to 
deal specifically with problem heroin users.  The outreach workers 
should seek out-of-treatment heroin users, make referrals to 
specialist agencies, deliver advice about methods to prevent overdose 
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with methadone and heroin, and distribute material on safer injecting, 
and needle exchange.  Outreach workers should also seek to establish 
and maintain contact with persons who have discontinued substitute 
prescribing and determine those factors which have influenced 
treatment termination.  This information could then be fed back to 
treatment agencies, not for monitoring purposes but to assist 
agencies in identifying programmatic issues that might assist 
treatment retention. 
 
6.17 Counselling should be offered to clients in receipt of methadone.  
 
Although counselling in conjunction with methadone treatment 
produces more favourable outcomes than methadone alone (pages 29-
31), a policy of mandatory counselling ignores the importance of 
matching individual needs with treatment options.  Moreover, not all 
methadone clients are in need of intensive counselling.  Some evidence 
suggests that other support services, e.g., employment skills training, 
can contribute to more favourable outcomes (page 30), however, few 
studies have examined this issue.  Mandated long-term counselling is 
not recommended, however, all clients should be required to undergo 
counselling during the early stages of treatment and some clients 
should be entitled to long-term counselling if needed and desired.  The 
frequency of counselling should depend on the needs of the individual.  
If one goal is to reduce the frequency of injection, then the issue of 
needle fixation should be addressed during counselling 
 
6.18 Counselling should address issues pertaining to post-traumatic 
stress. 
 
N. Ireland has experienced widespread political conflict and several 
persons have been exposed to extreme violence.  Research has found 
high rates of posttraumatic stress disorder (PTSD) in post-conflict 
societies (de Jong et al., 2001; see also page 12).  Other research has 
found linkages between exposure to traumatic events and post-
traumatic stress disorder (PTSD) (Breslau et al., 1999) and between 
PTSD and drug use (Bremmer et al., 1996; Chilcoat and Breslau, 1998).  
Still other research has found that drug misusers have high rates of 
PTSD and this co-morbidity has implications for treatment retention 
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(Back et al., 2000).  Some methadone clients will need counselling that 
focuses on traumatic experiences relating to the wider N. Ireland 
political conflict. 
 
Additionally, other support services should include a focus on child 
care, improving parenting skills, improving family relationships, 
identifying employment and education opportunities, and addressing 
acute needs such as housing (Effective Interventions Unit, 2001).   
 
6.19 It is recommended that crèche facilities be implemented at 
specialised drug treatment centres, to enable parents with young 
children to have greater access to treatment.   
 
Issues relating to child care may reduce the likelihood that some 
parents will participate in methadone treatment (pages 52-53).  The 
provision of crèche facilities in specialised drug treatment sites might 
increase treatment participation and retention among parents.    
A total of four of five of the Consultant Psychiatrists report that 
child care issues do not appear to be a major treatment barrier to 
female parents, although all four indicate that the majority of their 
patients are male.  It is important to note that one would need to 
conduct research with women heroin users who have not participated 
in treatment because of child care problems in order to investigate 
the matter fully.  CP 5 mentions that women can use child care 
problems as an excuse for not participating in treatment.  A CAT 
staff member reports that issues surrounding child care have 
surfaced for some women in treatment.  A second CAT staff person 
notes that although the agency in which s/he works has not 
incorporated substitute prescribing (except for detox), s/he notes 
that significant numbers of women in treatment for alcoholism have 
had child care problems, and at least one facility in N. Ireland has 
implemented crèche facilities for parents receiving treatment or 
support services for alcohol problems.  CP 2 suggests that the 
“service must be perceived as “beneficial” in order for prospective 
female patients with children to come forth for treatment.  
Consistent with the literature, four of five CPs acknowledged that 
methadone rather than Subutex was appropriate for use among 
pregnant women.   
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APPENDIX: DHSSPS response to the recommendations contained in the 
report “Review of Research on Substitute Prescribing for Opiate 
Dependence and Implications for N.  Ireland” by Dr Karen McElrath 
Recommendation 1:  Methadone maintenance be made available as a 
treatment option to individuals dependent on heroin.    
DHSSPS Response:  Accept.   
The Department  is satisfied that the review of the literature and the experience 
of service deliverers support the availability of maintenance therapy/substitute 
prescribing in Northern Ireland.   The Department will establish an 
Implementation Group to oversee how this issue should be progressed.   
The Department acknowledges that the research evidence base for methadone 
is stronger than that for other drugs, and that the concerns outlined by Dr 
McElrath, especially in relation to buprenorphine, are reasonable.   However, it is 
clear from Dr McElrath’s report that there is significant support for buprenorphine 
amongst consultant psychiatrists in Northern Ireland, and there are a number of 
clients currently in receipt of buprenorphine.  If practitioners follow Orange Book18 
guidelines when prescribing buprenorphine, the Department considers that it 
should support these practitioners in the management of clients in receipt of 
buprenorphine.  To do otherwise in the absence of strong evidence in relation to 
negative effects of buprenorphine would risk creating a two-tier service.    The 
Department also has to consider the position of those patients for whom 
                                                 
18 “Drug Misuse and Dependence – Guidelines on Clinical Management”, issued in 1999 by the 
Department of Health; the Scottish Office Department of Health; the Welsh Office; and the 
Department of Health and Social Services, Northern Ireland.  This publication is commonly 
referred to as the “Orange Book”.   
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methadone has been tried but has not worked.  Practitioners may need an 
alternative therapy and buprenorphine could well provide this.   
The Department will continue to monitor the research position with regard to all 
drugs used for substitute therapy and will review this position if the need arises.   
Recommendation 2:  A maximum length of time in methadone 
treatment should not be imposed.    
DHSSPS Response:  Accept.   
The Department accepts the view that where appropriate,  maintenance therapy 
produces better results than reduction strategies.  Although regular review of 
treatment is essential, and accepting that there will be circumstances in which it 
will be appropriate for patients to move from a maintenance programme to a 
reduction/detoxification programme, the Department recognises that 
maintenance is a valid therapy in its own right. 
 Recommendation 3:  DHSSPS does not implement a central register 
that would collect information on persons in receipt of methadone.    
DHSSPS Response:  Not accept. 
The Department does not accept this recommendation for a number of reasons.  
First, there is a legal requirement for doctors treating addicts to notify the Addicts 
Index under Regulation 3 of the Misuse of Drugs Regulations (Northern Ireland) 
2002.    
Secondly, in relation to individual clients, there will be a need for a mechanism to 
ensure that multiple scripting from a variety of sources does not take place.  The 
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research evidence strongly suggests that abuse in this way with consequent 
diversion of substitute drugs to the illegal market is likely to be a significant 
problem, and most jurisdictions have had to implement mechanisms to prevent 
this.  The precise nature of such controls will be determined by the 
Implementation Group which will be set up to oversee practice in relation to 
substitute prescribing, but the Department’s view is that this is likely to involve 
some sort of monitoring system that will be capable of identifying the prescription 
and dispensing of substitute drugs to individual users.   
Finally, it is clear that the establishment of substitute prescribing services will 
come under close scrutiny and monitoring data will be required to assess the 
efficacy of the intervention; to provide data for evaluation; and to provide public 
confidence in the policy. 
Recommendation 4:  Liquid rather than injectable methadone should 
be used for methadone maintenance.    
DHSSPS Response:  Accept. 
The Department does not see any strong case for the availability of injectable 
methadone at this time.   
Recommendation 5:  Methadone should be the preferred substitute 
drug for heroin  dependence, however, clinical discretion with regards to 
the choice of substitute drug should be acknowledged.    
DHSSPS Response:  Accept with qualification.   
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The Department acknowledges that, in individual circumstances,  the choice of 
substitute drug used should be based on clinicians’ assessment of the patient 
including taking into account the patient’s views.   See response to 
Recommendation 1.   
Recommendation 6:  At present, heroin maintenance should not be 
offered as a treatment option.   
DHSSPS Response:  Accept. 
The Department agrees that it is not appropriate to introduce heroin maintenance 
in Northern Ireland at this time.  The relatively low numbers of problem heroin 
users in Northern Ireland; lack of familiarity of practitioners and dispensers with 
substitute programmes;  the high (thrice-daily) dosing requirement and 
associated logistical and resource costs militate against the introduction of heroin 
maintenance, especially given the equivocal nature of the research evidence.   
Recommendation 7:  Diagnosis and assessment of drug dependence 
should be guided by the recommendations issued by the Department of 
Health as well as experts from Glasgow and Edinburgh.    
DHSSPS Response:  Accept with qualification.   
The Department endorses the view that diagnosis and assessment should be 
guided by the Orange Book19.   However the Department also considers that 
treatment should be guided by best practice from a wide variety of locations and 
                                                 
19 Although the  Orange Book was published by the Department of Health, the guidelines are 
jointly agreed between the four UK jurisdictions. 
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considers that limiting the input of expertise to Glasgow and Edinburgh is too 
restrictive. 
Recommendation 8:  Initial dosage levels should be monitored very 
closely.  DHSSPS implement a flexible methadone dosing policy.    
DHSSPS Response:  Accept. 
The Department accepts that the evidence in the report is clear in that trying to 
use minimalist prescribing which is not flexible to user need is counterproductive.  
This applies to any substitute drug, not just methadone.   
Recommendation 9:  Prescribers must be provided with very detailed 
information on drug interactions.   
DHSSPS Response:  Accept. 
The Department acknowledges that this is essential.   
Recommendation 10:  Where possible, it is recommended that shared 
care protocols for the treatment of heroin dependence be implemented. 
DHSSPS Response:  Accept with qualification. 
In light of small numbers of problem users likely to avail of treatment, and the fact 
that substitute prescribing is new in Northern Ireland, it will be appropriate that in 
the initial phases of the policy for secondary care should have the responsibility 
for the initiation of maintenance treatment and that GPs should liaise with 
secondary care in the treatment of patients as appropriate.  The Department is of 
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the view that, at least initially, one shared care monitoring group would be 
appropriate for all of Northern Ireland. 
Recommendation 11:  Persons who are dependent on heroin should be 
provided with various methods for accessing substitute drugs.   
DHSSPS Response:  Accept with qualification.   
The setting up of substitute prescribing services from a low baseline may initially 
restrict points of access on a purely logistical/resource basis.   The 
Implementation Group will have to take these factors into account.   
Recommendation 12:  Methadone consumption should be supervised 
for the first six months of treatment, and perhaps longer for some clients.     
DHSSPS Response:  Accept with qualification. 
Experience from elsewhere suggests that diversion of drugs prescribed for 
substitution purposes can be a significant problem and that supervised 
consumption is an effective measure which can be used to reduce the risk of this 
occurring.  Supervised consumption also acts as a reassurance to prescribers as 
it minimises the likelihood that medicines that they prescribe will subsequently 
end up being used by anybody other than the patient for whom it was intended.  
The Department thus supports the contention that the consumption of substitute 
drugs, including methadone and buprenorphine, be supervised. 
The Department is also of the view that in the initial stages of the implementation 
of a substitute prescribing regime consumption should continue to be supervised 
indefinitely.  This practice of supervised consumption should continue until the 
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Department is persuaded that a policy of allowing take-home doses can be 
operated that minimises the likelihood of any one other than the patient taking 
the substitute medication.  The Implementation Group should draw up guidelines 
bearing this position in mind.  Take-home doses should be minimised so that 
they are allowed only in exceptional circumstances, and guidelines need to be 
clear on precisely when this can occur and the safeguards that need to be 
introduced if take-home doses are to be permitted.   
Recommendation 13:  Implement a monitoring system for tracking 
methadone-related deaths. 
DHSSPS Response:  Accept with qualification 
The Department recognises that if substitute prescribing is implemented then it 
will be necessary to try and ascertain if any subsequent deaths are related to 
substitute medication.  Collating such data retrospectively is complicated and  it 
should be noted that patients who are under a maintenance therapy regime 
might also have access to drugs from another source.   
Recommendation 14:  Urinalysis should be used only as a method to 
monitor treatment progress and as a tool to assist with the prevention of 
overdose. 
DHSSPS Response:  Accept. 
Positive urine tests should be discussed with user and not automatically lead to 
treatment termination.  The Department also considers that urinalysis results 
have a place in the wider monitoring and evaluation of substitute therapy 
regimes.   
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Recommendation 15:  The number of persons in receipt of methadone 
and other substitute drugs for maintenance should be monitored closely. 
DHSSPS Response:  Accept. 
The Department accepts this recommendation.  This seems to support the need 
for some form of register unlike Recommendation 3. 
Recommendation 16:  Develop outreach teams in various parts of 
Northern Ireland.   
DHSSPS Response:  Accept. 
The Implementation Group should determine the best way of achieving this.   
 
Recommendation 17:  Counselling should be offered to clients in receipt 
of methadone. 
DHSSPS Response:  Accept. 
The Department consider that counselling should be offered, but not made 
compulsory for clients to accept.  It would also be essential to ensure  that 
counsellors are appropriately qualified and have access to clinical supervision. 
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Recommendation 18:  Counselling should address issues pertaining to 
post-traumatic stress. 
DHSSPS Response:  Not accept. 
This recommendation is written specifically in the context of political situation in 
Northern Ireland and in particular the high level of violence that has pertained 
over the past 30 years or so.  The Department considers that post-traumatic 
stress disorder has a number of other causes, eg road traffic accidents, family 
deaths, serious illness etc.   Counselling should address all of patient’s relevant 
needs where appropriate and it cannot be assumed that post-traumatic stress 
disorder is a factor in each case of drug misuse and/or the desire for 
maintenance therapy.  For this reason Department believes that counselling 
should only consider this issue if the need is identified.   
Recommendation 19:  It is recommended that crèche facilities be 
implemented at specialised drug treatment centres, to enable parents with 
young children to have greater access to treatment.    
DHSSPS Response:  Accept with qualification. 
The Department accepts this but acknowledges that there will be logistical issues 
for treatment centres and there is also the issue of resources which will need to 
be addressed.   
 
 
